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SUMMARY
This thesis consists of three decision making topics in two healthcare applications
using operations research methodologies.
The first application is prenatal screening for Down syndrome (DS) which is a
common type of chromosomal abnormality. Prenatal screening for pregnant women,
based on multiple serum and ultrasound markers, is non-invasive and used to assess
the risk of having a DS baby. A woman with a risk higher than a predefined risk-cutoff
value of prenatal screening, i.e., a positive screening result, typically undergoes an
invasive diagnostic test, such as amniocentesis, as a follow-up procedure to confirm
that her fetus is affected. The risk-cutoff value of DS prenatal screening plays an im-
portant role. On one hand, a lower risk-cutoff value elevates the risk of false positives,
and on the other hand, a higher risk-cutoff value increases the risk of false negatives.
In practice, a one-size-fits-all type of risk-cutoff value of 1 in 270 is usually used for
prenatal-integrated screening for DS. The objective of this application is to determine
the optimal risk-cutoff values from the individual and population’s perspectives.
The first topic focuses on the individual perspective. Women considering DS
screening usually face two major adverse outcomes: undetected DS live births due
to false negatives, and euploid procedure-related fetal losses due to false positives.
Evidence shows that women perceive the two outcomes very differently. However, no
guidelines exist for setting an appropriate risk-cutoff value based on women’s different
preferences. We capture the relative preferences using a ratio of weights (penalties),
and formulate an optimization model to minimize the weighted sum of the two adverse
pregnancy outcomes.
xii
The second topic is from the population’s perspective. Although using an appro-
priate one-size-fits-all cutoff value can achieve a high overall detection rate, it usually
also brings in undesirably high false positive rates in older ages. Therefore, we ex-
plicitly add an upper-bound constraint to every single age for fairness and maximize
the overall detection rate with those constraints.
The solution methodologies in this application combine the techniques of integer
programming and Monte Carlo simulations. We find the preference-sensitive and
age-specific risk-cutoff values have the potential to improve pregnancy outcomes and
patient satisfaction. Our framework for DS prenatal screening can shed some lights on
the optimal decisions in similar settings with a risk-cutoff value to designate positive
or negative results.
The second application focuses on a capacity allocation problem in a school-based
asthma care model, which is faced by Children’s Healthcare of Atlanta to improve
the health outcomes of pediatric asthma patients within metro Atlanta. In particu-
lar, the objective is to maximize the effectiveness of a school-based asthma program
by deciding dynamically: (i) which schools to visit, and (ii) if a school is visited,
which group of patients in this school to schedule for a limited number of clinical ap-
pointment slots. For this purpose, we propose a finite-horizon dynamic programming
model which combines a clinic disease model of childhood asthma with operational
decisions. We formulate a mixed-integer programming (MIP) for solving this model
and propose two computationally-efficient and competitive heuristic solutions based
on this MIP formulation. We parameterize our proposed models using data of a local
public school district (Atlanta Public Schools district) and quantify the percentages of
capacity allocated between patients in the worst illness states (treatment-prioritized
capacity allocation) and patients in the moderate illness states (prevention-prioritized
centered capacity allocation). We establish the following findings: (1) as capacity in-
creases and planning horizon extends, more patients will be able to end up in the best
xiii
illness states, (2) our index-based heuristic consistently has a small gap compared to
the optimal solution and it usually allocates more capacity to sickest patients, while
the optimal solution usually has a smarter balance of allocating capacity between
treating the sickest patients and preventing moderately sick patients from deteriorat-
ing, (3) capacity allocation are widely spread out among the public schools and driven
by larger sizes of asthma patients who are sicker. We further quantify the value of




In health systems, many applications to improve health outcomes boil down to op-
timization problems, which can be too complicated to solve for optimality manually.
It is useful to develop rigorous mathematical models to assist decision making. This
thesis presents three topics on decision making optimizations with operations research
methodologies. The first two topics focus on optimizing decisions in prenatal screen-
ing for Down syndrome (DS). Among those topics, we consider the problem from both
individual and populations’ perspectives. The third topic solves a capacity allocation
problem in a school-based asthma care model.
1.1 Preference-Sensitive Risk-Cutoff Values for Prenatal-
Integrated Screening Test for Down Syndrome
For a pregnant woman considering prenatal screening for early detection of DS, there
are at least two major adverse outcomes of interest: undetected DS live births and
euploid procedure-related fetal losses. Although evidence highlights the heterogeneity
in women’s preferences about the two adverse outcomes, the risk-cutoff value of 1/270
is commonly used for recommending a diagnostic test in practice. This topic focuses
on the individual perspective.
1.1.1 Objectives
Since the guidelines of setting risk-cutoff values based on preferences are not in place,
we propose that preference-sensitive risk-cutoff values should be considered instead
of one-size-fits-all type of risk-cutoffs. The objective of this study is to assess the
1
impact of womens preferences for different pregnancy outcomes on the optimal risk-
cutoff values for integrated screening, which has a higher detection rate compared to
other maternal serum and ultrasound screening tests.
1.1.2 Methodology
We build a Monte Carlo simulation model of 100,000 singleton second-trimester preg-
nancies to assess the probabilities of DS live births and euploid procedure-related
fetal losses for various risk-cutoff values, since there exist no explicit formulas to
capture the relationship between risk-cutoff values and the adverse outcomes. To
capture how undesirable some women may view an undetected DS live birth relative
to a euploid procedure-related fetal loss, we use a ratio W1 : W2 of weights (penal-
ties) assigned to these two adverse pregnancy outcomes. We formulate the problem
as an unconstrained optimization to minimize the weighted sum of the two adverse
pregnancy outcomes, and determine the optimal risk-cutoff value through brute force
enumeration over a wide range of risk-cutoff values.
1.1.3 Contribution
We have shown that a one-size-fits-all risk-cutoff value, such as 1/270, may not always
be the best choice, depending on the preferences of women. Preference-sensitive risk-
cutoff values for DS screening have the potential to improve the pregnancy outcomes
and patient satisfaction.
Our method of determining a threshold based on women’s preference is applicable
to integrated screening for DS as well as all other DS screening modalities or even
screening test in other health systems as long as they utilize a screen threshold to
designate a positive or negative test.
We have published a peer-reviewed paper [93] on this topic. The paper is a joint
work with Dr. Aaron B. Caughey in Department of Obstetrics and Gynecology at
Oregon Health & Science University. In addition, we acknowledge the suggestions
2
and feedbacks from Dr. Scott Grosse.
1.2 Age-based Differences in the Predictive Accuracy of a
One-Size-Fits-All Risk-Cutoff Value in Prenatal Inte-
grated Screening for Down Syndrome
This and next chapters consider the population’s perspective. A one-size-fits-all cutoff
value is typically used in Down syndrome screening, impacting diagnostic decisions.
Prior studies reported variations in age-related detection and false positive rates for
combined screening but not for integrated screening.
This chapter is to assess variation in detection and false positive rates and adverse
pregnancy outcomes across different age groups when a one-size-fits-all risk-cutoff
value, such as 1/270, is used in integrated screening for Down syndrome. A Monte
Carlo simulation was utilized to estimate the detection and false positive rates as well
as adverse pregnancy outcomes. Using a one-size-fits-all risk-cutoff value, such as
1/270, can result in considerably high variations in detection and false positive rates
across maternal ages, and lead to a higher than the minimum possible total number of
adverse outcomes. Our findings indicate that the one-size-fits-all risk-cutoff value of
1/270, commonly used in DS screening, should be revisited and alternative (possibly
age-based) cutoff values and strategies should be considered. This chapter gives rise
to the question of how to select optimal risk-cutoff values, which is the focus of the
next chapter.
1.3 Setting Age-specific Risk-cutoff Values in Prenatal In-
tegrated Screening for Down Syndrome Considering the
Variation of False Positive Rates across Age Groups
The use of a single risk-cutoff value in prenatal integrated screening for Down syn-
drome causes high variation in detection and false positive rates across maternal ages.
3
1.3.1 Motivation
The objective of this study is to determine the optimal age-specific risk-cutoff values
that maximize the overall detection rate, while reducing the variation with respect to
false positive rates across different ages.
1.3.2 Methodology
We present a flexible mathematical modeling-based framework to determine the op-
timal age-specific and age-group-specific risk-cutoff values. While the age-specific
policy is more flexible and can result in better outcomes, the age-group-specific pol-
icy may be easier to implement. We utilize Monte Carlo simulations to assess the
detection and false positive rates (and corresponding adverse pregnancy outcomes)
under different risk-cutoff value choices. We present examples of policies for age-
specific and age-group-specific risk-cutoff values, each resulting in fewer total number
of adverse outcomes and a lower false positive rate in women of ages 36-50, compared
with the commonly used single risk-cutoff value of 1/270.
1.3.3 Contribution
Age-specific risk-cutoff values have the potential to simultaneously improve pregnancy
outcomes and variation false positive rates across age groups in prenatal integrated
screening for Down syndrome.
1.4 Capacity Allocation in a School-Based Asthma Care
Model for Pediatric Patients
Asthma is the most common childhood chronic illness [23] which affects 6.3 million
(8.6% of) American children [64]. In addition, asthma is among the leading causes of
severe health outcomes for children, including hospitalizations, emergency department
visits, and missed school days [60]. During 2013, asthma resulted in 2,742 hospitaliza-
tions and 26,302 emergency room visits among children in Georgia [44]. About 1 in
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2 children with asthma limited their usual activities, and 58% of school-aged asthma
patients missed at least one school day due to asthma [44]. In fact, asthma can be
well controlled by appropriate self-managements. The large amount of severe health
outcomes nationwide and in Georgia highlights the lack of access and adherence to
disease management care for childhood asthma.
Children’s Healthcare of Atlanta (Children’s) at Hughes Spalding is planning a
school-based program with one mobile asthma clinic to improve the access and adher-
ence to asthma care by outreaching underserved school-aged asthma patients in metro
Atlanta. The 40-foot long, 8-foot wide vehicle (mobile asthma clinic) will be staffed
by one physician, two licensed practical or registered nurses, and one drive. All the
services they provide, such as diagnosis and medication, are free of charge to patients
in this program. Similar programs have been established for more than a decade
in several metropolitan areas in the United States and have shown improvements in
patients’ health outcomes.
1.4.1 Objectives
The service capacity for a mobile asthma clinic is limited to 16 patients a day and
4 days a week. Therefore, it is critical to determine how to allocate capacity among
and within schools in metro Atlanta. The objective of this study is to maximize the
aggregate quality of life (QoLs) scores of the asthma patient population by making
two-level decisions: (i) which schools to visit, and (ii) which groups of patients within
the schools to schedule for a limited number of appointments.
1.4.2 Methodology
We focus on building a mathematical framework to determine the capacity alloca-
tion. In particular, we propose a finite-horizon dynamic programming model and
formulate a mixed-integer programming (MIP) for solving this model. In addition,
we develop two heuristic algorithms, which can be easily implemented in practice. We
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parameterize our model using the data of a local public school district and extensive
computational experiments show that the two heuristics are computationally-efficient
and competitive in the quality of solutions.
1.4.3 Contribution
First, to our best knowledge, we are the first in literature to consider the two-level
operational decisions integrated with clinical models of disease progression, and tac-
tically address the capacity allocation problem. The solutions we proposed can not
only establish monthly appointment schedules within a certain school but also de-
termine the capacity allocation among different schools by considering the disease
dynamics in each school. Second, we formulate a MIP by considering operational
constraints and disease progressions for solving the finite-horizon dynamic program-
ming model. Using efficient optimization solvers, we can quantify the decisions for
school systems of a fairly large size. Third, we develop two heuristic solutions. One
is an index-based greedy algorithm, which is computationally efficient and easily im-
plementable. The other heuristic algorithm is to solve a series of nested versions of
MIP relaxation models, which requires more memory and computational time but
results in a negligible gap from the optimal solutions of the original MIP. Fourth, we
parameterize our model using the data of a local public school district of 89 schools
and 5975 asthma patients. Our extensive computational experiments suggest that
although it is intuitive to prioritize treatment of patients who are in the worst illness
states, it is in fact more beneficial to appropriately divide capacity between treatment
and prevention. In other words, while treating the sickest patients, we also want to
prevent those patients in slightly better illness states from deteriorating to worse ill-
ness states. The findings can be applied in practice to determine the optimal schedule
of the school-based asthma program.
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CHAPTER II
PREFERENCE-SENSITIVE RISK-CUTOFF VALUES FOR
PRENATAL-INTEGRATED SCREENING TEST FOR
DOWN SYNDROME
2.1 Introduction
Down syndrome (DS, Trisomy 21) is the most common chromosomal abnormality
among live births and one of the leading causes of mental retardation. The prevalence
of DS in the United States increased from 9.5 to 14 per 10,000 live births between
1979 and 2006 [25, 26], despite an increasing array of screening tests during that time.
Each year, about 1 of every 691 babies is born with DS [71]. Population prevalence
of DS in the United States is about 8 per 10,000 people, according to a study [73]
published in 2013.
For a pregnant woman considering prenatal screening for DS, there are at least
two major adverse outcomes of interest: (i) undetected DS live birth, that is, birth of a
baby with undetected DS prior to delivery; and (ii) euploid procedure-related fetal loss,
due to an invasive diagnostic test, such as amniocentesis. The likelihoods of these two
outcomes depend on the risk-cutoff value used in recommending amniocentesis. A low
risk-cutoff value results in a high detection rate but also leads to a higher false-positive
rate, giving rise to more unnecessary amniocenteses and euploid procedure-related
fetal losses. On the other hand, a higher risk-cutoff value results in fewer avoidable
fetal losses but leads to a higher false-negative rate and more undetected DS live
births. Currently, about one to five out of every 1000 pregnant women undergoing
amniocentesis experience a procedure-related fetal loss [18, 67].
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Evidence suggests that women have different preferences about the pregnancy out-
comes. For example, cross-sectional studies of diverse pregnant women showed that
substantial differences exist in preferences with respect to the two adverse outcomes
[55, 57, 58]. Another study showed that women who perceive themselves at higher
risk or are more concerned about having a DS live birth may prefer to maximize
detection rate at the expense of a higher false-positive rate, while those who are more
concerned about a procedure-related fetal loss may prefer to minimize the risk of an
avoidable fetal loss at the expense of a higher false-negative rate [92]. Despite the ex-
isting evidence that women have different preferences, no preference-based guideline
of DS screening is in place [56, 59].
There are several studies [11, 17, 19, 20, 49, 68] utilizing quality-adjusted life
years to capture womens preferences in cost-effectiveness analysis. However, these
studies commonly use 1/270 as the risk-cutoff value.[11] Walker et al.[92] recently
acknowledged that different women may weigh pregnancy outcomes differently and
considered the effects of such differences in choosing the risk-cutoff values for quadru-
ple serum test (quad screen). Compared with the quad screen, integrated screening
has a higher detection rate.[1, 84] However, the question of how the risk-cutoff val-
ues should be set in integrated screening to capture womens various risk preferences
remains unanswered.
The purpose of this study is to determine the optimal risk-cutoff value of inte-
grated screening by considering risk preferences of women with respect to pregnancy
outcomes. Based on a mathematical model, we (i) estimated the likelihoods of unde-
tected DS live births and euploid procedure-related fetal losses over a wide range of
risk-cutoff values; (ii) explored the conditions under which a certain risk-cutoff value
became optimal; and (iii) quantified the impacts of using the optimal risk-cutoff values




Our study focused on the integrated screening strategy, which assesses the DS risk by
synthesizing biomarkers in the first trimester (nuchal translucency, pregnancy asso-
ciated plasma protein A, and free β human chorionic gonadotropin) and the second
trimester (alpha-fetoprotein, human chorionic gonadotropin, unconjugated estriol,
and Inhibin-A) with maternal age.[89] Those women who have a higher calculated
risk of DS compared with a pre-defined risk-cutoff value of integrated strategy are of-
fered the option of diagnostic tests, which might lead to procedure-related fetal losses.
We assumed that women with a lower risk of DS do not consider any diagnostic tests.
Note that DS pregnancies might also result in spontaneous miscarriages or stillbirths
at a higher rate than euploid pregnancies.[61] Figure 1 depicts the integrated screening
strategy and the resulting pregnancy outcomes.
2.2.2 Decision model
We built a mathematical model to quantify the optimal risk-cutoff values given the
womens preferences, represented by different weights (penalties) assigned to differ-
ent pregnancy outcomes: W1 for an undetected DS live birth and W2 for a euploid
procedure-related fetal loss. We focused on the relative weight, that is, W1 : W2,
rather than absolute values. For example, if an undetected DS live birth is twice
as undesirable for a woman as a euploid procedure-related fetal loss, then we have
W1 : W2 = 2 : 1. We tested various values for W1 : W2 ratio to quantify the impact
of different relative preferences on the optimal risk-cutoff values.
We used Monte Carlo simulation [11, 17, 89, 90] to assess the probability of an
undetected DS live birth, probability of a procedure-related fetal loss, detection rate
(DR), and false-positive rate (FPR) for various cutoff values ranging from 1/2000 to
1/2. Because the risks of DS are different across age groups, we reported performance
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Figure 1: Algorithm for integrated strategy from the second trimester to term. The
second-trimester diagnostic test is amniocentesis. r, the risk-cutoff value used; DR(r),
detection rate for the risk-cutoff value r; FPR(r), false-positive rate for the risk-
cutoff value r; PDiag, consent rate to diagnostic test given positive results of screening
tests; PLoss, procedure-related fetal-loss rate due to amniocentesis; PTer, termination
rate given positive results of diagnostic tests; PStill, spontaneous fetal-loss rate of DS
pregnancies.
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measures for the overall population and selected age groups (20, 30, 35, and 40 years
old), and compared different risk-cutoff values within certain age groups.
2.2.3 Data and model parameters
Based on the maternal age distribution from the United States National Vital Statis-
tics birth data between years 2008 and 2010,[29] we sampled 100,000 affected pregnan-
cies and unaffected pregnancies, respectively, to calculate DR and FPR of integrated
screening test for each age group. For a given risk-cutoff value, to estimate DR, we
divide the number of affected cases with a risk exceeding the risk-cutoff value by
100,000. Similarly, to estimate FPR, we divide the number of non-affected cases with
a risk exceeding the risk-cutoff value by 100,000. Marker levels (in multiples of me-
dian among unaffected pregnancies) of integrated screening tests were sampled based
on the distributions reported in the Serum, Urine, and Ultrasound Screening Study
(SURUSS)[90, 91] using MATLAB (The MathWorks Inc., Natick, MA, 2012). We cal-
culated the risk of DS using the standard method of Wald and Hackshaw (2000).[88]
In addition, we assumed 100% sensitivity and specificity of amniocentesis.[34, 51]
Table 1 presents the model parameters and corresponding sources.
2.2.4 Sensitivity analysis
We conducted one-way sensitivity analysis on a consent rate to amniocentesis given
positive results of screening tests (PDiag) and procedure-related fetal loss rate due to
amniocentesis (PLoss), and we solved for the optimal risk-cutoff values for the extreme
values (i.e. lower and higher levels) of these two parameters. In addition, we also
conducted probabilistic sensitivity analysis for the two rates based on 1,000 samples
drawn from triangular distributions representing the uncertainty in each rate. The
lower limit, upper limit, and mode of the triangular distribution for PDiag were 50%,
70%, and 57.1%, respectively.[11] Similarly, the lower limit, upper limit, and mode of
the triangular distribution for PLoss are 0.1%, 0.5%, and 0.3%, respectively.[18, 67]
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Table 1: Values of parameters.














60% Estimated based on
Natoli et al. (2012)
[66]
PStill Spontaneous fetal
loss rate due to
Down syndrome
23% Morris et al.
(1999)[61]
PLoss Procedure-related
fetal loss rate due
to amniocentesis
0.3%(0.1−0.5%) Caughey et al.
(2006) [18]; Odibo et
al. (2008) [67]
W1 : W2 Ratio of penalties





2:1, 1:1, 1:2 We vary this ratio





Table 2 and Figure 2 summarize the performance measures for various risk-cutoff val-
ues, including DR, FPR, probabilities of undetected DS live births (P1), and euploid
procedure-related fetal losses (P2). In the overall simulated population at the second
trimester, 0.237% has a DS affected fetus, which is in line with the DS prevalence of
1 in 420 in Walker et al.[92] As the risk-cutoff value decreases from 1/50 to 1/1000,
DR increases from 82.0% to 95.8% and FPR increases from 0.7% to 8.8%. For a
particular risk-cutoff value (e.g. 1/270), the DR and FPR are lower in younger age
groups (e.g. 83.5% and 1.5%, respectively, for 20-year-old women) than those in older
age groups (e.g. 96.6% and 15.4%, respectively, for 40-year-old women). As expected,
probabilities of an undetected DS live birth and a procedure-related fetal loss are also
lower in younger age groups.
The optimal risk-cutoff values for the overall population and each age group are
presented in Table 3. When the relative penalty a woman places on an undetected DS
live birth (W1) versus a euploid procedure-related fetal loss (W2) is the following: (i)
higher (W1 : W2=2:1), the optimal risk-cutoff value is ‘low’, 1/915; (ii) the same (W1 :
W2=1:1), the optimal risk-cutoff value is ‘medium’, 1/454; (iii) lower (W1 : W2=1:2),
the optimal risk-cutoff value is ‘high’, 1/237. For the overall population or a given
age group, as the relative preferences change, the optimal risk-cutoff value changes
significantly. For example, for age 30 years, for the relative penalties (W1 : W2) of 2:1,
1:1, and 1:2, the optimal risk-cutoff values are 1/864, 1/451, and 1/238, respectively.
Furthermore, for a specific combination of age group and preferences, the optimal
risk-cutoff value can range from 1/994 to 1/221.
Depending on the optimal risk-cutoff values reflecting womens preferences, the
proportion of the total number of adverse outcomes may change. For example, if
the 1/270 threshold was applied to a cohort of 4 million women (approximately the
annual number of live births in the United States [29]), there would be about 636
13
Table 2: Measured outputs at various pre-defined risk-cutoff values. P1, likelihood
of an undetected Down Syndrome live birth in a cohort of pregnant women (entire
population or a certain age group); P2, likelihood of a procedure-related fetal loss in a
cohort of pregnant women (entire population or a certain age group); DR, detection
rate of integrated screening test, the proportion of affected pregnancies with positive
results of screening tests; FPR, false-positive rate of integrated screening test, the
proportion of unaffected pregnancies with positive results of screening tests.
Risk-cutoff value Age P1(%) P2(%) DR(%) FPR(%)
1/270 Overall 0.016 0.005 91.3 3.2
20 0.011 0.003 83.5 1.5
30 0.014 0.004 86.4 2.3
35 0.024 0.009 91.6 5.4
40 0.040 0.026 96.6 15.4
1/50 Overall 0.033 0.001 82.0 0.7
20 0.020 0.001 70.4 0.3
30 0.027 0.001 74.2 0.4
35 0.052 0.002 81.7 1.2
40 0.113 0.007 90.2 4.3
1/500 Overall 0.011 0.009 93.7 5.3
20 0.009 0.005 87.3 2.7
30 0.011 0.007 89.8 4.0
35 0.017 0.015 94.1 8.8
40 0.024 0.038 97.9 22.8
1/1000 Overall 0.008 0.015 95.8 8.8
20 0.006 0.008 91.0 5.0
30 0.007 0.012 93.0 7.1
35 0.010 0.024 96.3 14.3
40 0.013 0.056 98.9 33.2
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Figure 2: Probabilities of euploid procedure-related fetal losses and undetected DS
live births for various age groups as a function of the risk-cutoff value. Each hor-
izontal line segment at each point denotes the possible range of the probability of
procedure-related fetal losses when PLoss (0.1−0.5%) and PDiag (50−70%). Probabil-
ity of procedure-related fetal losses: proportion of procedure-related fetal losses in a
maternal age group (i.e. the number of procedure-related fetal losses divided by the
total number of pregnancies in that maternal age group); Probability of undetected
DS live births: proportion of undetected DS live births in an age group (i.e. the
number of undetected DS live births divided by the total number of pregnancies in
that maternal age group).
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Table 3: Optimal risk-cutoff values for various preferences and age groups. P1, like-
lihood of an undetected Down Syndrome live birth in a cohort of pregnant women
(entire population or a certain age group); P2, likelihood of a procedure-related fe-
tal loss in a cohort of pregnant women (entire population or a certain age group);
DR, detection rate of integrated screening test, the proportion of affected pregnancies
with positive results of screening tests; FPR, false-positive rate of integrated screen-
ing test, the proportion of unaffected pregnancies with positive results of screening
tests; Proportion of women with amniocentesis: number of women who undergo am-
niocentesis divided by total number of women in a cohort; Proportion of women with
positive amniocentesis results: number of women who undergo amniocentesis and
receive positive diagnostic results divided by total number of women in a cohort.

























Overall 1/915 0.008 0.014 95.6 8.2 4.83 0.13
20 1/898 0.006 0.008 90.5 4.5 2.62 0.05
30 1/864 0.008 0.011 92.4 6.3 3.66 0.07
35 1/912 0.011 0.023 96.1 13.4 7.83 0.20
40 1/994 0.013 0.056 98.9 33.1 19.45 0.85
The same 1:1
Overall 1/454 0.012 0.008 93.4 4.9 2.90 0.13
20 1/430 0.009 0.004 86.5 2.3 1.36 0.04
30 1/451 0.011 0.006 89.3 3.7 2.16 0.07
35 1/472 0.017 0.014 93.9 8.5 5.01 0.20
40 1/446 0.027 0.036 97.7 21.3 12.80 0.84
Lower 1:2
Overall 1/237 0.017 0.005 90.7 2.9 1.76 0.12
20 1/235 0.012 0.002 82.6 1.3 0.79 0.04
30 1/238 0.015 0.003 85.7 2.0 1.22 0.07
35 1/231 0.026 0.008 90.9 4.8 2.92 0.19
40 1/221 0.045 0.023 96.1 13.4 8.38 0.83
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undetected DS live births (resulting from 825 false-negative screening tests) and 219
euploid procedure-related fetal losses, that is, a total of 855 adverse outcomes. If
a risk-cutoff value of 1/454 was used instead, there would be about 485 undetected
DS live births and 333 euploid procedure-related fetal losses, a total of 818 adverse
outcomes. Although 1/454 increases the number of euploid procedure-related fetal
losses by 114, it decreases the number of undetected DS live births by 151 and the
total number of adverse outcomes is reduced by 37. For those women who treat the
two outcomes as equally undesirable, the 1/454 risk cutoff would be preferable to the
1/270 cutoff value, which is commonly used in practice.
2.3.1 Sensitivity analysis
Table 4 presents the results of a one-way sensitivity analysis of two parameters:
consent rate to amniocentesis given positive results of screening tests (PDiag) and
procedure-related fetal loss rate due to amniocentesis (PLoss). Higher PDiag and PLoss
result in higher optimal risk-cutoff values. The results are sensitive to PDiag and PLoss.
When women weigh the two outcomes equally (W1 : W2=1:1), the optimal risk-cutoff
value can vary from 1/1561 to 1/225 depending on PDiag and PLoss (Table 4). Figure
3 shows the probabilistic sensitivity analysis results for PDiag and PLoss. Similar to
one-way sensitivity analysis, these results confirm that the optimal risk-cutoff values
are sensitive to these two parameters.
Table 4: Sensitivity analysis of optimal risk-cutoff values at different values of PDiag
and PLoss when W1 : W2=1:1.
PDiag
Optimal risk-cutoff value 50% 57.1% 70%
PLoss
0.5% 1/330 1/279 1/225
0.3% 1/532 Base case: 1/454 1/374
0.1% 1/1561 1/1336 1/1113
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Figure 3: Probabilistic sensitivity analysis of PDiag and PLoss based on 1000 samples
when W1 : W2=1:1. PDiag, consent rate to diagnostic test given positive results of
screening tests; PLoss, procedure-related fetal loss rate due to amniocentesis.
2.4 Discussion
We proposed a comprehensive model to select risk-cutoff values for the integrated
screening test.
Our analyses showed that if women have varying preferences, a one-size-fits-all
risk-cutoff value, such as 1/270, is not always the best choice, depending on the
preferences of women. For example, for some women, if an undetected DS live birth
is significantly more undesirable than a euploid procedure-related fetal loss,[55, 57, 58]
then a lower cutoff value would be more appropriate. Our proposed method ensures
that the cutoff value balances the risks of the adverse pregnancy outcomes depending
on a group of womens preferences; this is a step forward to personalized decisions.
The overall detection and false-positive rates cannot be improved simultaneously
by applying age-specific risk-cutoff values compared with using one risk-cutoff value
for all age groups. This may be due to the similarity of the optimal risk-cutoff values
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across different age groups, if preferences of pregnancy outcomes are the same for all
women (shown in Table 3).
The sensitivity analysis indicates that the optimal risk-cutoff value could vary
significantly for different values of positive results of screening tests (PDiag) and the
procedure-related fetal loss rate due to amniocentesis (PLoss). In particular, we find
that as PDiag or PLoss increases, using higher cutoff values would be more appropriate.
While we used population level average for PDiag, we acknowledge that it actually
varies significantly from one woman to another. Especially for those women who are
more likely to consent to amniocentesis, a higher cutoff value may reduce the overall
rate of procedure-related fetal losses.
Despite the novel results of our study, it is not without limitations. Our results
are based on mathematical models with assumptions, not randomized controlled tri-
als (RCTs) or observational studies. For example, we treated the DS spontaneous
miscarriage rate (PStill) independent of the result of the integrated test, while the
SURUSS study [90, 91] noted that those pregnancies that end in spontaneous mis-
carriages tend to receive a higher risk score in screening tests. We also assumed
that women with a predicted risk of DS below the risk-cutoff value would not receive
a diagnostic test. Although imperfect, our mathematical model allows for testing a
spectrum of risk-cutoff values and differences in womens preferences, which is not pos-
sible in RCTs and observational studies. Another limitation is using the distributions
of marker levels from the SURUSS study in the UK, similar to other studies which
used the SURUSS trial for US-based [92] and Canada-based [39, 40] analysis. Hence,
the parameters (including means, standard deviations, correlation coefficients, and
truncation limits) may not well present the characteristics of women in the United
States or other countries. Decision-makers in the Unites States or other countries can
adjust marker levels based on local data to choose appropriate risk-cutoff values.
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In this study, we only focus on the integrated screening test and do not con-
sider the cell-free fetal DNA (cffDNA) test, a new method for DS screening that
has a higher detection rate and a lower false-positive rate than traditional screening
methods.31,32 [2, 35] Currently, cffDNA is not recommended for low-risk women.[2]
In current practice, ultrasound/serum screenings, including integrated, sequential,
contingent, quadruple, or combined tests, are still the most commonly used strate-
gies. However, our modeling framework is general and can easily be extended to
model other screening strategies and capture the improvements in detection and false-
positive rates. Further, given that any of these screening modalities utilize a screen
threshold to designate a positive or negative test, the findings that such a threshold
should be based upon women’s preferences are applicable.
2.5 Conclusion
Prenatal screening decisions need to take into account patient preferences for different
pregnancy outcomes when determining the risk-cutoff value. The model in our paper




AGE-BASED DIFFERENCES IN THE PREDICTIVE
ACCURACY OF A ONE-SIZE-FITS-ALL RISK-CUTOFF
VALUE IN PRENATAL INTEGRATED SCREENING FOR
DOWN SYNDROME
3.1 Introduction
Down syndrome (DS) is among the most prevalent genetic disorders in human beings.
Maternal serum and ultrasound screening are standard noninvasive prenatal screening
strategies administered to pregnant women to assess the risk of having a baby with DS.
Acknowledging the clinical availability and high accuracy of cell-free DNA (cfDNA)
screening, the American College of Obstetricians and Gynecologists and the Society
for Maternal-Fetal Medicine still suggest conventional screening methods [3] as the
most appropriate choice for most pregnant women. Among conventional screening
options for DS, this study focuses on prenatal integrated screening, which combines
both first and second trimester biomarkers [11] and has the highest detection rate
(DR) [1], compared to the first trimester combined screening and the second trimester
triple and quadruple screenings.
There are two major adverse outcomes of interest in DS screening: (1) an un-
detected DS case prior to delivery, which is referred to as undetected DS live birth,
and (2) a euploid procedure-related fetal loss due to an invasive diagnostic test such as
amniocentesis, following a DS screening test with “positive” result. The likelihoods of
these two outcomes depend on the risk-cutoff value used in the screening test, and the
corresponding test accuracy. In practice, a one-size-fits-all type of risk-cutoff value,
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such as 1/270 [11], is typically used to designate the outcomes of a maternal serum
screening, which measures the DS risk as a continuous variable, as positive and neg-
ative. “Detection rate” (or equivalently sensitivity) and “false positive rate” (FPR,
or equivalently 1specificity) refer to the percentage of pregnancies labeled as positive
by the test, correctly and incorrectly, respectively. “False negative rate” (FNR) is
defined as 1−DR. Hence, a lower DR (equivalently, higher FNR) increases adverse
outcome (1), that is, undetected DS live births, and a higher FPR increases adverse
outcome (2), that is, euploid procedure-related fetal losses.
Several studies have reported differences in preferences among women regarding
the two main adverse pregnancy outcomes [55, 57, 58, 92, 93]. In addition, the risk
of DS [62] changes significantly with age. This raises the question of whether the
commonly used risk-cutoff value of 1/270 is indeed the best option for all ages.
The purpose of this study is to assess the variation in detection and false positive
rates (and hence, the undetected DS live births and euploid procedure-related fetal
losses) across different age groups when a one-size-fits-all risk-cutoff value, such as
1/270, is used in integrated screening for DS. Prior researches [38, 69, 83, 85, 93]
acknowledged variations in age-related detection and false positive rates in the context
of first and/or second trimester testing. Among them, Yan et al. [93] is particularly
relevant, which, by taking individual patients perspective, showed that the optimal
risk-cutoff values could be very different depending on womens personal preferences.
However, to our knowledge, no prior population-based study has considered the
effect of using a single cutoff value in integrated screening on the health outcomes dis-
parities with respect to detection and false positive rates across different age groups,
which is the focus of this study.
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3.2 Methods
Prenatal integrated screening test considers six biomarkers [11, 89] including nuchal
translucency, pregnancy associated plasma protein A (PAPP-A) in the first trimester,
and alpha-fetoprotain, human chorionic gonadotropin (hCG), unconjugated estriol,
and Inhibin-A in the second trimester. We used a previously validated Monte Carlo
simulation [93] to sample from the biomarker distributions reported in the Serum,
Urine, and Ultrasound Screening Study (SURUSS) [91]. The risk of a DS pregnancy
is calculated using the biomarkers and maternal age [88]. In particular, we sampled
800,000 affected pregnancies, calculated the risk for each pregnant woman, counted
the number of pregnant women with a risk higher than the given risk-cutoff value
(i.e., the pregnancies identified as positive by the test), and divided this number by
800,000 to derive DR. Similarly, we sampled 800,000 unaffected pregnancies, calcu-
lated the risk for each pregnant woman, counted the number of pregnant women with
a risk higher than the given risk-cutoff value, and divided this number by 800,000 to
derive FPR. Similar to Yan et al. [93], we used a Monte Carlo simulation to calcu-
late DRs and FPRs for risk-cutoff values: 1/63, 1/137, 1/270, 1/397, 1/485, 1/536,
1/1052, across different ages. 1/270 is a commonly used risk-cutoff value in practice
and all the values listed here result in FPRs between 1% and 10%. In addition, we
also reported the total number and probabilities of adverse outcomes, i.e., undetected
DS live births (DSLs), and euploid procedure-related fetal losses (EFLs) due to am-
niocentesis, respectively, out of a cohort of 4 million pregnancies (approximately the
annual size of live births in the United States [87]). The parameters [93] to calculate
the adverse outcomes include uptake rate of amniocentesis (57.1%), spontaneous fetal




Table 5 and Figure 4 summarize the overall DRs and FPRs of various one-size-fits-all
risk-cutoff values. Figure 5 illustrates the tradeoff between probabilities of DSLs and
EFLs. The expected numbers of DS live births and euploid procedure-related fetal
losses are presented in Table 5 and Figure 6. Using the risk-cutoff value of 1/270
results in an overall DR of 91.01%, an overall FPR of 3.56%, and a total number of
937 adverse outcomes. For cutoff value 1/270, the DR and FPR for each maternal
age are presented in Figure 7. The FPRs range from 1.59% to 33.8% and DRs range
from 82.60% to 98.73% for ages 20–50. In addition, we present age-based FPRs and
DRs for various alternative risk-cutoff values in Figures 8–9.
Table 5: Overall DRs and FPRs, DSLs, and EFLs of 1/270 and alternative one-
size-fits-all risk-cutoff values. Note that 1/270 is highlighted. Among the alternative
risk-cutoff values, 1/397, 1/485, and 1/536 results in the same total number of DSLs
and EFLs, which is smaller than that of 1/270. However, the numbers of DSLs and
EFLs are different under each of the three risk-cutoff values. DRs, detection rates;
FPRs, false positive rates; DS, Down syndrome; DSLs, undetected DS live births;
EFLs, euploid procedure-related fetal losses.
One-size-fits-all risk-cutoff values
Model outputs 1/63 1/137 1/270 1/397 1/485 1/536 1/1052
Overall DR (%) 83.03 87.65 91.01 92.64 93.40 93.76 95.86
Overall FPR (%) 1.00 2.00 3.56 4.85 5.67 6.12 10.00
DSLs 1319 956 696 568 511 483 319
EFLs 66 135 241 330 387 415 683
DSLs + EFLs 1385 1091 937 898 898 898 1002
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Figure 4: Overall detection and false positive rates (DRs and FPRs) of 1/270 and
alternative one-size-fits-all risk-cutoff values.
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Figure 5: Probabilities of undetected Down syndrome live births (DSLs) and euploid
procedure-related fetal losses (EFLs) of 1/270 and alternative one-size-fits-all risk-
cutoff values.
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Figure 6: Number of undetected Down syndrome live births (DSLs), euploid
procedure-related fetal losses (EFLs), and total adverse outcomes of one-size-fits-all
risk-cutoff values between 1/1052 and 1/63.
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Figure 7: Detection and false positive rates across maternal ages (blue dots) using
the risk-cutoff value of 1/270. The vertical (red) dashed lines show the level of false
positive rates of 5%, 10%, 15%, 20%, 25%, and 30%.
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Figure 8: False positive rates in individual ages under different risk-cutoff values.
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Figure 9: Detection rates in individual ages under different risk-cutoff values.
3.4 Discussion
3.4.1 Considerable variation in DR and FPR across ages
Figures 8-9 show that when a single cutoff value is used, the DRs and FPRs (and
hence, adverse pregnancy outcomes) exhibit significant variations across maternal
ages. For example, with a risk-cutoff value of 1/270, the FPR for women younger
than 35 years is below 5% while for women older than 45 years the FPR exceeds
30%. Regardless of the cutoff value, both the DRs and FPRs increase with maternal
age (Figures 8-9). However, variation exists in womens preferences with respect to
the pregnancy outcomes [57, 58, 62, 92, 93]. For example, given that the chance of
a future pregnancy for older women is significantly lower, it is not clear that they
would prefer this combination of high DR and high FPR (resulting from the risk-
cutoff value of 1/270), since a high FPR could lead to a procedure-related fetal loss
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due to a follow-up diagnostic test. Hence, it is important to consider the patient age
and preferences, along with other factors, in the choice of the risk-cutoff value.
3.4.2 Number of adverse outcomes
Note that the commonly used risk-cutoff value 1/270 approximately balances the
false negative rate (100% − 92.29% = 7.71%) and FPR (7.07%) for a 36-year-old
woman. Recall that the false negative rate (FNR) is 1−DR, i.e., the percentage of DS
pregnancies not detected by the test. However, 1/270 leads to an imbalance between
FNR and FPR in other maternal ages; for example, for 40-year-old women the FNR
is 3.62% and FPR is 16.43% (Figure 7). In addition, 1/270 does not minimize the
total number of adverse outcomes, resulting in 696 undetected DS live births and 241
euploid procedure-related fetal losses, with a total of 937 adverse outcomes across all
ages (Table 5). In comparison, 1/485 results in 511 undetected DS live births and
387 euploid procedure-related fetal losses, with a total of 898 adverse outcomes. In
general, as the cutoff value decreases, both DR and FPR increase, i.e., the number
of undetected DS live births decreases and the number of euploid procedure-related
fetal losses increases. While it is not possible to improve both adverse outcomes at
the same time by choosing a cutoff value other than 1/270, it is possible to change
(and improve) the total number of adverse outcomes, as well as their distribution
across different age groups. For example, 1/397, 1/485, and 1/536 all result in 898
total number of adverse outcomes, but the number of undetected DS live births and
euploid procedure-related fetal losses are different under each of the three risk-cutoff
values.
3.5 Conclusion
Currently, a single one-size-fits-all risk-cutoff value is often used to label the DS risk
of a pregnancy as positive or negative based on the results of integrated screening.
This study shows that the use of a single risk-cutoff value can lead to high variation
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of false positive rates and detection rates across maternal ages, impacting the number
of adverse outcomes (undetected DS live births and euploid procedure-related fetal
losses) across ages. Further, the commonly used risk cutoff value, 1/270, does not
minimize the total number of adverse outcomes. These results highlight the need
for revisiting the risk cutoff values used in integrated screening, and possibly adjust-




SETTING AGE-SPECIFIC RISK-CUTOFF VALUES IN
PRENATAL INTEGRATED SCREENING FOR DOWN
SYNDROME CONSIDERING THE VARIATION OF
FALSE POSITIVE RATES ACROSS AGE GROUPS
4.1 Introduction
Down syndrome (DS, Trisomy 21) is a common type of chromosomal abnormality
associated with an increasing risk of several problems such as mental retardation
and congenital heart diseases, with a prevalence of about 1 in every 691 births in
the United States [71]. Prenatal DS screening and diagnostic decisions affect about
overall 4 million live births [87].
Prenatal integrated screening, a serum and/or ultrasound markers-based non-
invasive test, is commonly used to assess the risk of having a baby with Down syn-
drome. The result is reported as positive (negative) when the derived risk is higher
(lower) than a predefined risk-cutoff value. The outcome is a false positive when the
screening result is positive but the baby does not have Down syndrome; conversely,
the outcome is a false negative when the screening result is negative but the baby does
have Down syndrome. The use of a higher risk-cutoff value reduces the false positive
rate, but increases the false negative rate, and vice versa. The false negative and
false positive rates relate to adverse outcomes of (i) an undetected DS case prior to
delivery, which is referred to as undetected DS live birth, and (ii) a euploid procedure-
related fetal loss due to an invasive diagnostic test such as amniocentesis, following
a DS screening test with a positive screening result. The detection rate refers to the
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fraction of pregnancy outcomes which are identified correctly by the screening result.
In current practice, a one-size-fits-all type value, typically 1/270, is commonly used
for prenatal-integrated screening test for DS [11].
A recent study [94] has shown that the use of a one-size-fits-all risk-cutoff value
in prenatal integrated screening may result in undesirably high false positive rates,
and in turn, potentially higher rates of euploid procedure-related fetal losses, among
older women.
The purpose of this study is to develop a framework to identify the optimal age-
specific risk-cutoff values that maximize the overall detection rate while considering
variation across different maternal ages with respect to the false positive rates. We
proposed a flexible mathematical model (based on integer programming), and solved
it using the state-of-the-art optimization solvers. To prepare the input to the opti-
mization framework, we developed a simulation model to assess the performance of
the computed optimal risk-cutoff values versus the commonly used one-size-fits-all
risk-cutoff value.
4.2 Methods
We developed an integer programming (IP) model for determining the optimal risk-
cutoff values of prenatal-integrated screening. In our models, the objective is to
maximize the overall detection rate, and the constraints include upper-bounds on false
positive rates based on age or age group: (1) age-specific risk-cutoff values for each
individual age (A-IP), and (2) age-group-specific risk-cutoff values (AG-IP)to ensure
that the same risk-cutoff value applies to women within an age group. The constraints
enforce that the false positive rate for any age (or age group) does not exceed a selected
maximum acceptable value. A-IP is more flexible, resulting in a specific cutoff value
for each age, and is expected to lead to better outcomes; however, the large number
of risk-cutoff values may be challenging for implementation in practice. In AG-IP,
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there is a risk-cutoff value for each age group (rather than for each age), and hence,
the number of risk-cutoff values is smaller and this policy provides a balance between
the quality of outcomes and ease of implementation in practice.
4.2.1 Screening strategy and Monte Carlo simulations
Integrated screening is a commonly used prenatal test to assess the risk of Down syn-
drome in a pregnancy. The screening test is based on biomarkers of nuchal translu-
cency, pregnancy associated plasma protein A (PAPP-A) in the first trimester as
well as alpha-fetoprotain, human chorionic gonadotropin (hCG), unconjugated es-
triol, and Inhibin-A in the second trimester [11, 89]. The risk of a DS pregnancy is
calculated using the biomarkers and the maternal age [88] and if the calculated risk
exceeds a pre-defined risk-cutoff value, the result of the test is marked as positive.
Women with a positive test result (i.e., a higher calculated risk than the risk-cutoff
value) may consider amniocentesis. On the other hand, women whose test results
are negative (i.e., the calculated risk is lower than the risk-cutoff value) often do not
consider amniocentesis. Since the classification of the test result is not perfect, there
are two potential adverse outcomes: (i) a false positive, followed by an amniocentesis
possibly leading to a procedure-related fetal loss, and (ii) a false negative, leading to
an undetected DS live birth. Detection rate refers to the fraction of DS pregnancies
(also referred to as “affected” pregnancies) where DS is identified correctly by the
test (note that the detection rate is equal to 1 minus the false negative rate).
We utilized a previous validated Monte Carlo simulation [93] to calculate the
detection and false positive rates given a risk-cutoff value. In each run of Monte Carlo
simulation, we sampled 800,000 affected (unaffected) pregnancies, applied risk-cutoff
values, and calculated the detection rate (false positive rate) with respect to each risk-
cutoff value [94]. In particular, the distributions of log10 biomarkers in affected and
unaffected cohorts of pregnant women are modeled as truncated multivariate Gaussian
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distributions with means, correlation matrices, and truncation limits reported in the
Serum, Urine, and Ultrasound Screening Study (SURUSS) [90]. The uptake rate of
amniocentesis, spontaneous fetal loss rate due to DS, and procedure-related fetal loss
rate due to amniocentesis are set to 57.1%, 23%, and 0.3% respectively [93].
4.2.2 Integer programming model
We formulated two IP models, A-IP and AG-IP, with an objective function of maxi-
mizing the overall detection rate and constraints to ensure age-specific or age-group-
specific, as well as overall upper bounds on false positive rates. The complete model
formulations of A-IP and AG-IP can be found in §4.2.2.2. The models are solved
using Gurobi (Gurobi Optimization, Inc. 2016).
4.2.2.1 Model inputs
To prepare the input parameters for the model, we utilized the Monte Carlo sim-
ulations described in §4.2.1. We generated an input table which contains a set of
risk-cutoff values along with their corresponding detection and false positive rates for
each maternal age (12 to 50 years old). A given risk-cutoff value results in a partic-
ular detection rate and false positive rate for a certain age. Hence, for the model to
capture a wide range of possibilities in terms of (detection and false positive rates)
combinations for different ages, it needs a carefully selected set of risk-cutoff values
as input. We started with a basic set of risk-cutoff values ranging from 1/450 to 1/51
(with increments of 1 in the denominator). We then generated a set of risk-cutoff
values corresponding to detection rates ranging from 50% to 99% (with increments
of 1%) and false positive rates ranging from 1% to 40% (with increments of 0.5%) for
each age. The union of these sets of potential risk-cutoff values forms the input for
both A-IP and AG-IP. The corresponding steps to the above description for selecting
the set of possible risk-cutoff values (to be the input into the model) are:










one by one to each age (12 to 50 years old) and calculated the detection rate
and false positive rate for each age and risk-cutoff value pair.
Step 2 Inversely calculate risk-cutoff values corresponding to a specific de-
tection or false positive rate: We used a bisection search to find out the risk-
cutoff value that would result in a certain detection rate (50%, 51%, · · · , 99%)
or a false positive rate (1%, 1.5%, 2%, · · · , 39.5%, 40%) for a given age. The
feasibility of bisection search is guaranteed by the analytical result of Observa-
tion 1. The stopping criteria for our bisection search is the detection rate (or
false positive rate) is within a 0.001% relative error rate of the target value of
detection rate (or false positive rate). This step generates 129 risk-cutoff values
for each age and guarantees that the risk-cutoff values in each age can cover the
detection or false positive rates of interest.
Step 3 Risk-cutoff values from Step 2 in a different age: We applied the cutoffs
generated from Step 2 for one age to each of other ages to make sure each
age has the same set of risk-cutoff values. This step applies additionally 4902
(= 129× 38) risk-cutoff values to each age.
A simplified version of Step 2: we randomly pick 30-years-old age as our base
age and calculate the 129 risk-cutoff values using bisection searches as described in
Step 2. Using the explicit formula in the condition of Proposition 1, we can directly
map the risk-cutoff values calculated for the base age to those for the other 38 ages
without any more inverse calculation, which is computationally intensive. On average,
each bisection search takes 516 seconds using MATLAB parallel computing (two AMD
Athlon II CPU cores running at 3.0 GHz with 6 GB of memory). In total, we can
save more than 2.5× 106 seconds using this simplified Step 2.
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4.2.2.2 Model formulation
Sets and parameters used in A-IP (IP for age-specific risk-cutoff values) and AG-IP
(IP for age-group-specific risk-cutoff values) are defined in Table 6. Each age group
will be assigned one and only one risk-cutoff value, which is represented by decision
variables in Table 6.
Table 6: Risk-cutoff value optimization using integer programming – sets, parame-
ters, and decision variables.
Sets
I Set of maternal ages, I = {12, 13, · · · , 49, 50}
Ri Set of candidate risk-cutoff values for maternal age i, i ∈ I
Ik Age group k,
⋃
k=1,...,K Ik = I, Ik
⋂
Ik′ = ∅,∀k, k′ ∈ {1, 2, · · · , K}
Parameters
K Total number of age groups considered in AG-IP
DRi,r Detection rate of using risk-cutoff value r in age i, i ∈ I, r ∈ Ri
FPRi,r False positive rate of using risk-cutoff value r in age i, i ∈ I, r ∈ Ri
γi Upper-bound of false positive rate in age i, i ∈ I
θ Upper-bound of overall false positive rate
Pi Maternal age distribution in year 2014 [87], i ∈ I
Q0i Age risk of Down syndrome [62], i ∈ I
ε Upper-bound of relative error of risk-cutoff values within an age group
Decision Variables
xi,r Binary decision variable, xi,r =

1, r is assigned to age i
0, otherwise
, i ∈ I, r ∈ Ri
We presented two policies of age-specific risk-cutoff values and age-group-specific
risk-cutoff values respectively. While the former provides more flexibility and better
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outcomes, the latter aims to provide a balance between high performance and easiness
of implementation.
Age-specific risk-cutoff values integer programming (A-IP)


























FPRi,rxi,r ≤ θ; (3)
∑
r∈Ri
xi,r = 1 ∀i ∈ I; (4)
xi,r ∈ {0, 1} ∀i ∈ I, r ∈ Ri. (5)
Constraints (2) ensure that false positive rate of each age does not exceed the
age-based upper bound, and constraint (3) ensures that the upper bound of overall
false positive rate. Constraints (4) guarantee that each age is assigned a risk-cutoff
value. The objective is to maximize the overall detection rate.
Age-group-specific risk-cutoff values integer programming (AG-IP)
We consider age-group-specific risk-cutoff values. In particular, the risk-cutoff
value is a step function of age group. Therefore, we add two sets of constraints to
make sure the risk-cutoff values within the same age group are close enough (with
ε = 10−5).
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rxi,r ∀i, j ∈ Ik, k ∈ {1, · · · , K}. (7)
4.2.3 Examples: age-specific and age-group-specific risk-cutoff values
We proposed two policies: age-specific risk-cutoff values (corresponding to A-IP)
and age-group-specific risk-cutoff values (corresponding to AG-IP). While the former
provides more flexibility and better outcomes, the latter offers ease of implementation
while still improving the outcomes compared to the one-size-fits-all risk-cutoff value
currently used in practice. The following are examples of these policies with specific
parameter settings:
• A-IP Eexample: This example A-IP policy ensures upper bounds on age-
specific false positive rates as shown in Figure 10 and also ensures a 4% upper
bound on the overall false positive rate across all ages.
• AG-IP Example: We divided the cohort into three age groups: ages 12–29,
30–35, and 36–50. This example AG-IP policy ensures upper bounds on false
positive rates, namely, 5%, 10%, and 30% for each of the three age groups,
respectively (Figure 10) and also ensures a 5% upper bound on the overall false
positive rate.
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Upper bound of FPR in A−IP
Upper bound of FPR in AG−IP
Figure 10: Age-specific and age-group specific upper bounds on FPR in Examples 1
and 2, used as input to solve the models A-IP and AG-IP. γi of A-IP is a linear trans-
formation of FPR curve of 1/270. In particular, γi = 3% + (25%− 3%)(FPRi,1/270−
FPR12,1/270)/(FPR50,1/270−FPR12,1/270). FPR under the one-size-fits-all risk-cutoff
value of 1/270 is provided for comparison. FPR, false positive rate.
4.2.4 Performance measures
We reported the detection rate (DR) and false positive rate (FPR) for each age (or age
group) resulting from the solutions, i.e., set of risk-cutoff values, of A-IP and AG-IP,
applied to a cohort of 4 million simulated women. We also reported the numbers of (i)
undetected DS live births (DSLs), as well as (ii) euploid procedure-related fetal losses
(EFLs), corresponding to DR and FPR, respectively. We compared these results




In Table 7, we compare the overall DR, FPR, EFL and DSL of the two examples
with the one-size-fits-all risk-cutoff value of 1/270. The one-size-fits-all risk cutoff
value of 1/270 results in DR=91.01% and FPR=3.56%. The age-specific risk-cutoff
values in Example 1 result in DR=91.48% and FPR=4.00%. The age-group-specific
risk-cutoff values in Example 2 result in DR=92.46% and FPR=4.99%), respectively,
comparing to 12.21% under the risk-cutoff value of 1/270. In Examples 1 and 2, the
overall DR is higher, and the DRs and FPRs in younger age groups 12–39 and 30–35
are also higher than those under 1/270. Compared to 1/270, in Examples 1 and 2
the EFLs are higher and the DSLs are lower, resulting in a lower total number of
adverse outcomes. Figures 11–13 present age-(group-)specific risk-cutoff values of our
two examples, and the age-specific FPR, DR resulting from the age-(group-)specific
risk-cutoff values.
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Table 7: Overall and age-group-dependent detection rate (DR), false positive rate
(FPR), Down syndrome live births (DSLs), euploid procedure-related fetal losses
(EFLs), and total number of adverse outcomes (Total) under the (i) one-size-fits all
risk cutoff value 1/270, (ii) age-specific cutoffs (solutions of A-IP), and (iii) age-group-
specific cutoffs (solutions of AG-IP).
Risk-cutoff values




Overall DR (%) 91.01 91.48 92.46
FPR (%) 3.56 4.00 4.99
DSLs 696 659 586
EFLs 241 269 341
Total 937 928 927
Ages 12–29 DR (%) 83.47 85.92 87.65
FPR (%) 1.78 2.53 3.29
DSLs 288 246 216
EFLs 68 98 128
Total 356 344 344
Ages 30–35 DR (%) 88.39 89.61 91.68
FPR (%) 3.53 4.32 6.08
DSLs 237 211 171
EFLs 75 91 129
Total 312 302 300
Ages 36–50 DR (%) 95.69 94.89 94.98
FPR (%) 12.21 10.27 10.41
DSLs 171 202 199
EFLs 98 80 84
Total 269 282 283
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Figure 11: Solutions (risk-cutoff values) of age-specific risk-cutoff model (A-IP) and
age-group-specific risk-cutoff model (AG-IP). The one-size-fits-all risk-cutoff value
1/270 is provided for comparison.
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Figure 12: False positive rate resulting from the age-specific and age-group-specific
risk-cutoff values in Examples 1 and 2 (output from the solutions of A-IP and AG-IP).
False positive rate under the one-size-fits-all risk-cutoff value of 1/270 is provided for
comparison.
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Figure 13: Detection rate resulting from the age-specific and age-group-specific risk-
cutoff values in Examples 1 and 2 (output from the solutions of A-IP and AG-IP).
Detection rate under the one-size-fits-all risk-cutoff value of 1/270 is provided for
comparison.
4.4 Discussion
The two examples demonstrate that age-specific and age-group-specific risk-cutoff
values have the potential to improve outcomes, e.g., by better controlling FPRs in
older women without increasing the total number of overall adverse outcomes across
all ages. The two examples are provided for illustration purposes only, whereas the
actual choice of parameters for the potential implementation of age-specific or age-
group-specific risk-cutoff values in practice would require a better understanding of
the preferences of women across different age groups. The developed models are
very flexible and provide the opportunity for what-if analysis and easy evaluation of
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various parameter settings for age-specific and age-group-specific policies.
The results indicate a tradeoff (correlation) between DR and FPR. As shown in
Table 7, age-specific and age-group-specific risk-cutoff values result in higher overall
DR and higher overall FPR, whereas both the FPR and DR are lower for older
women, compared to 1/270. To achieve a higher overall DR compared to that under
1/270, age-specific and age-group-specific risk-cutoff values slightly increase DR and
FPR (resulting in lower DSLs and higher EFLs) in younger age groups. Hence, the
optimal age-based risk-cutoff values balance the DR and FPR (and the corresponding
adverse outcomes) among younger and older age groups.
4.5 Conclusion
Variation of FPRs across maternal ages resulting from a single one-size-fits-all risk-
cutoff value has been highlighted in previous studies. We proposed two type of poli-
cies: age-specific and age-group-specific risk-cutoff values, and showed that those
policies have the potential to mitigate the high variation of FPRs as well as to reduce
the total number of adverse outcomes compared to commonly used risk-cutoff value
of 1/270. The mathematical framework is very flexible to determine the age-(group-
)specific risk-cutoff value based on the practical requirements.
4.6 Technical Appendix
We present the following findings in two observations and three propositions.
1. Detection (false positive) rate decreases with risk-cutoff value for a given age.
2. Detection (false positive) rate increases with age for a given risk-cutoff value.
3. Detection and false positive rate in two ages are equal when their risk-cutoff
values satisfy an explicit formula.
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4. We can always find a one-size-fits-all risk-cutoff value, which is optimal to min-
imize the positive-weighted sum of DSLs and EFLs.
5. We can always find a one-size-fits-all risk-cutoff value, which is optimal to max-
imize the overall detection rate with an upper bound constraint of the overall
false positive rate.
Before getting into the proof, we introduce notations in addition to the ones in the
previous sections. The post test risk given log10 biomarkers (denoted as Z ∈ R6) and
maternal age i is denoted as Q1i (Z) and it is calculated using standard method in [88],
i.e., Q1i (Z) =
φ1(Z)Q0i
φ1(Z)Q0i +φ2(Z)(1−Q0i )(1−S)
, where φ1(·) and φ2(·) are probability density
functions of affected and unaffected pregnancies respectively, and S is a constant
denoting the spontaneous fetal loss rate due to DS. Let ri denote the risk-cutoff value
for age i. DRi,ri(FPRi,ri) is the detection (false positive) rate for age i with risk-
cutoff value ri. By definition, detection (false positive) rate is the portion of affected








Observation 1. If r1, r2 ∈ (0, 1), and r1 ≤ r2, then DRi,r1 ≥ DRi,r2 and FPRi,r1 ≥
FPRi,r2, ∀i ∈ I.
Proof. Since r1 ≤ r2, then {Z : Q1i (Z) > r1} ⊇ {Z : Q1i (Z) > r2}.







φ1(Z)dZ = DRi,r2 .
And similarly FPRi,r1 ≥ FPRi,r2 , ∀i ∈ I.
Observation 2. If i ≤ j, then DRi,r ≤ DRj,r and FPRi,r ≤ FPRj,r, ∀r ∈ (0, 1).
Proof. Consider the set of biomarkers of age i:
{






























Hence, {Z : Q1i (Z) > r} ⊆ {Z : Q1j(Z) > r}.
Therefore, DRi,r ≤ DRj,r and FPRi,r ≤ FPRj,r.













, then DRi,ri = DRj,rj and
FPRi,ri = FPRj,rj , ∀i, j ∈ I.
Proof. Same as the proof above, we have
{

























, then {Z : Q1i (Z) > ri} = {Z : Q1j(Z) > rj}.
Therefore, DRi,ri = DRj,rj and FPRi,ri = FPRj,rj .
Proposition 2. There exists a one-size-fits-all type of risk-cutoff value which can
minimize the positively weighted sum of the two adverse outcomes, i.e., for any












has an optimal solution as r12 = r13 = · · · = r50 = DL/(DL+ (1−S)W1/W2), where
N denotes the total number of pregnant women in the cohort.








1(Q1i (Z) > ri)φ2(Z)dZ. (10)
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+W2(1−Q1i (Z))1(Q1i (Z) > ri)DL].


























i (Zj) ≤ ri)(1− S) +W2(1−Q1i (Zj))1(Q1i (Zj) > ri)DL
]
.
where Ni = NPi denotes the total number of women in age i, and Zj follows pdf of
Q0iφ1(Z) + (1−Q0i )φ2(Z) for a given age i.
In other words, we can interpret the calculation of the two adverse outcomes in two
equivalent ways: one uses prior probability and the other uses posterior probability.
• A cohort’s point of view with age risk (prior probability): This is exactly (8).
In the first term, NPiQ
0
i (1−DRi,ri)(1− S), is the expected number of DS live
births in maternal age i with risk-cutoff value ri, and W1 is the weight for an
undetected DS live birth. Similarly, the number of euploid procedure-related
fetal losses with ri in age i can be calculated as NPi(1 − Q0i )FPRi,riDL with
weight W2.
• A woman’s point of view with post test risk (posterior probability): A cohort
consists of a large number of individuals and each individual woman (denoted





i (Zj) ≤ ri)(1− S) +W2(1−Q1i (Zj))1(Q1i (Zj) > ri)DL. (11)
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First we optimize the problem for each woman. If we can find a common
optimal solution which is independent of log10 biomarkers Zj and age i, then
this solution will also be the optimal solution from the cohort’s point of view.
Note that the optimal risk-cutoff value r∗ for a given woman should satisfy:
r∗ ≤ p1 ∀p1 satisfying W1p1(1− S) ≤ W2(1− p1)DL; (12)
r∗ ≥ p2 ∀p2 satisfying W1p2(1− S) > W2(1− p2)DL. (13)
It implies that r∗ = DL/(DL + (1 − S)W1/W2), which can minimize (11) for each
woman. Apparently, it is independent of Zj and i, so it should also be the optimal
solution for (8).
Proposition 3. There exists a one-size-fits-all type of risk-cutoff value which can
maximize overall detection rate while keeping overall false positive rate no greater

















Pi(1−Q0i )FPRi,ri ≤ θ.
has an optimal solution the type of which is one-size-fits-all (r12 = r13 = · · · = r50).
Proof. Let r∗ = [r∗i ]i∈I denote an optimal age-specific solution of the problem. Be-
cause of the monotonicity of detection and false positive rates as functions of the






Pi(1−Q0i )FPRi,r∗i = θ.
On the other hand, we can use bisection search to find out the one-size-fits-all
type of risk-cutoff value that make the constraint tight, and denote the value as r0
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Pi(1−Q0i )FPRi,r0 = θ.
In addition, there must exist W1/W2 > 0 satisfying r
0 = DL/(DL+ (1− S)W1/W2).

































is a positive constant.
After multiplying a negative constant and adding a constant term, (14) is equiv-













According to Proposition 2, there exists a one-size-fits-all type of risk-cutoff value
r12 = r13 = · · · = r50 = r0 that is optimal to the optimization problem (15). This
implies that
F2([r
0, r0, · · · , r0]) ≤ F2(r∗)

























































CAPACITY ALLOCATION IN A SCHOOL-BASED
ASTHMA CARE MODEL FOR PEDIATRIC PATIENTS
5.1 Introduction
Asthma is a chronic disease of the lungs and the most common childhood chronic ill-
ness in the United States [23], affecting about 6.3 million (8.6% of) American children
[64]. In the state of Georgia, the asthma prevalence among children is even higher,
i.e., 10.8% with a 95% confidence interval of 9.1–12.7% [44]. Childhood asthma is
a leading cause of hospitalizations, emergency department visits, and missed school
days [60]. In the United States, 128,000 hospital discharges of children under 15 years
old had asthma as the first-listed diagnosis in 2010 [4]. During 2011, children under
15 years old had about 611,000 emergency department visits [22]. 13.8 million of
school days were missed due to asthma, and 49% of asthma patients between 5 and
17 years old reported at least one missed school days during 2013 [24].
Although not completely curable, severe health outcomes of asthma, including
hospitalizations, emergency department visits, as well as missed school days, can be
reduced or even eliminated if the disease is well managed. In addition, with the
proper treatment, asthma patients and their caregivers can keep the symptoms under
control and prevent damage to lungs [60]. The reason for severe outcomes occurring
every year mainly lies in the lack of access and adherence to appropriate asthma care.
On the other hand, a significant portion of pediatric asthma patients have limited or
no healthcare access while evidence suggests that lack of access is one of the leading
causes for severe asthma outcomes. In particular, children living in inner cities are
found to have an elevated risk of hospitalizations, emergency department visits, and
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deaths due to asthma [23].
Several school-based programs have been established to reduce severe health out-
comes and improve the quality of life among underserved children in several metropoli-
tan areas in the United States, including Baltimore [15], Chicago [72], Los Angeles
[52, 53], and St. Louis [86] among others. Those programs usually reach out to
schools proactively via units of mobile asthma clinics staffed by a team of specialists,
and work closely with school nurses to deliver care to underserved populations peri-
odically (typically on a monthly basis). Such programs were shown to improve overall
outcomes by improving access to care, increasing patient awareness and adherence
to treatment. In particular, studies assessing the success of the school-based models
have shown significant reductions in emergency room visits [15, 72], hospital days
[15, 72], and missed work days of caregivers [72] as well as significant increases in
symptom-free days and controller medication availability [15].
In the summer of year 2015, Children’s Healthcare of Atlanta (Children’s) Asthma
Center at Hughes Spalding, a local hospital network in the state of Georgia, started
to plan a school-based program with one unit of mobile care clinic for underserved
pediatric asthma patients in metro Atlanta. On October 31, 2016, the first mobile
asthma clinic was launched to serve metro Atlanta’s pediatric patients [78].
The mobile asthma clinic is a 40-foot long, 8-foot wide vehicle built specifically
for delivering pediatric health care services [76], and the program is funded by local
charities [75]. The asthma services, including screening and diagnosis, medication
prescriptions, and education, are free of charge to patients in this program [77]. The
mobile asthma clinic includes two patient examination rooms, a draw station, 1 pul-
monary function laboratory, and reception and waiting areas and is staffed by one
pediatric nurse practitioner, two licensed practical or registered nurses, and one mo-
bile outreach technician [78]. It runs four days a week and on average can take sixteen
appointments each day.
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In this paper, we focuses on building a mathematical framework to determine
the capacity allocation by answering two-level questions: (i) which schools to visit,
and (ii) if a school is visited, which groups of patients within the school to sched-
ule for a limited number of appointments. The objective is to maximize the health
outcomes measured in quality of life (QoL) months for the entire patient population.
In particular, we propose a finite-horizon dynamic programming model and formu-
late a mixed-integer programming (MIP) for solving this model. In addition, we
develop two heuristic algorithms, which can be easily implemented in practice. We
parameterize our model using the data of a local public school district and extensive
computational experiments show that the two heuristics are computationally-efficient
and competitive in the quality of solutions.
5.2 Literature Review
There have been several studies on the disparities of pediatric asthma care within
several states in the US. Garcia et al. [37] evaluate the geographic access to primary
and asthma specialist care on severe outcomes, including emergency department visits
and hospitalizations, of school-aged children (5–17 years old) in Georgia and North
Carolina. They find the association between spacial access and severe outcomes is
different across states. In particular, they show that access to primary care impact
more than access to specialist care on Georgia emergency department visits, and the
reverse applies for Georgia hospitalization. Fitzpatrick et al. [36] study the spatial
access to asthma and compare the access to asthma care in 14 states in the United
States. Bost et al. [16] compare the pediatric asthma service utilization, expenditures,
and treatment with medications in Georgia, Florida, and North Carolina during 2006-
2009 based on Medicaid claims data. In addition, the success and positive impacts
on health outcomes achieved by mobile asthma clinics have been demonstrated in
several observational studies [15, 52, 53, 72] with pre-post program comparisons.
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Disease modeling has been an important component in the public health research
to improve decision making. Ayer et al. [9] present a comprehensive survey of studies
on disease screening, especially cancer screening, management of chronic diseases, as
well as control of infectious diseases. They have pointed out the insufficiency and po-
tential in research of chronic disease by applying operations research and management
science techniques. Kucukyazici and Verter [54] review and highlight three studies
on community-based care management for chronic diseases, including mental health
care, post-stroke care, and asthma care. All those examples of disease management
embedded Markov models of disease progression or disease-specific chronic care pro-
cess. For disease modeling of asthma patients, Paltiel et al. [70] introduce a Markov
state-transition simulation model named “Asthma Policy Model”, which plays an im-
portant role in cost-effectiveness studies of various therapy options considering both
clinical and economic outcomes.
Decision making in resource allocation consists of a broad range of research prob-
lems featured by limited budgets, funding, health care personnels, medical devices
and equipments, vaccines or medicines, operation rooms, hospital beds, or appoint-
ments and so on. Griffin et al. [46] present a survey of resource allocation problems
for infectious diseases such as malaria prevention. In addition, there are many recent
studies on HIV-related resource allocation [33, 50], Hepatitis C treatment allocation
[10] and organ transplant [8, 14]. Appointment scheduling problems in health care
systems have been reviewed in Batun and Begen [12], Cayirli and Veral [21], Gupta
and Denton [47]. Adaptive behaviors, such as no shows in the setting of appointment
scheduling, have gained an increasing attention in recent literature [31].
However, there exist only few studies to combine clinical models of disease pro-
gression for asthma and operational constraints of the health system. Deo et al. [32]
build a Markov decision process (MDP) framework considering capacity allocation
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and disease progression to maximize quality adjusted life years of the patient popu-
lation, and apply the MDP model to a school-based asthma management program in
Chicago. On top of their model, Savelsbergh and Smilowitz [82] further optimize the
appointment schedule with no-show behaviors by incorporating patients’ time-of-day
preferences. However, the decisions in the two studies are based on a pre-defined
schedule of school visits so they optimized capacity allocation within one specific
school assuming that the school would be visited periodically.
As a newly developed school-based asthma program in metro Atlanta, the selec-
tion of schools is a critical component of the decision. However, to the best of our
knowledge, no asthma model has integrated clinical decisions with two-level oper-
ational decisions to allocate capacity among and within schools. In this study, we
aim to fill this gap. In addition, different from Deo et al. [32], we aggregate asthma
patients of the same illness level and consider the overall transition among illness
states as moving from one period to another. Consequently, our model becomes de-
terministic and can be characterized as decisions at the tactical level. In addition, we
formulate the problem as a mixed integer programming so that we are able to solve
efficiently for large scale school systems with large number of patients, and quantify
solutions as well as their performances, such as optimality gaps, which are extremely
useful for practice use.
5.3 Mathematical Model
Our goal is to maximize the aggregate quality of life (QoL) months of the asthma
patient population by making two-level decisions: (i) which schools to visit, and
(ii) which groups of patients within the schools to schedule for a limited number of
appointments. This problem can be viewed as a finite-horizon dynamic programming
(DP) model which combines operational decisions and a clinic model of childhood
asthma. To solve it, we formulate the capacity allocation problem as a mixed integer
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programming (MIP).
5.3.1 Assumptions and notations
We limit the visit of the mobile asthma clinic to one school per day, and we allow
to visit one school multiple times in a decision period, i.e., one month. We assume
that treatment occurs in each appointment. Since the treatment effect can last for
some time, we assume one patient can be scheduled for at most one appointment each
month. In addition, due to the existence of surveys and portable monitoring devices,
we assume a separate assessment mechanism from each appointment and we can reply
on school nurses to monitor the true illness states of each patient so that we can know
exactly the patients for whom we will schedule appointments. The sequence of events
in a period is presented as follows:
1. calculation of QoLs based on the state at the beginning of a period,
2. capacity allocation for the current period,
3. appointments of patients in the period (with treatment),
4. natural disease progression of all patients.
The notations used in our model are presented below:
• t: index of decision period (month), t = 1, . . . , T ;
• k: school index, k = 1, . . . , K;
• Nk: number of asthma patients in school k;
• B: capacity of appointments per day, B = 16 patients/day;
• C: number of service days in each month;
• i: index of illness degree, i ∈ I = {1, 2, . . .};
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• st,k,i: number of patients of illness degree i in school k at the begin of period
t, st,k,i ∈ R+ and
∑
i∈I st,k,i = Nk,∀t = 1, . . . , T , k = 1, . . . , K. In particular,
s1,k,i denotes the initial number of patients of illness degree i in school k;
• bi: quality of life (QoL) score of one patient of illness degree i;
• Rt(St): the total QALYs of the patient population in period t with state St =
[[st,k,i]i∈I ]k=1,...,K at the beginning of period t;
• xt,k: decision variable of number of days spending in school k in period t. xt,k
can take any non-negative integers no greater than C, i.e. xt,k ∈ {0, 1, 2, . . . , C};
• yt,k,i: decision variable of number of patients in illness degree i getting scheduled
for an appointment in school k in period t, yt,k,i ∈ {0, 1, 2, . . . , bst,k,ic};
• Denote at = [xt,k, [yt,k,i]i∈I ]k=1,...,K , ∀t = 1, . . . , T ;
• P : transition probability matrix for natural disease progression. In particular,
let Pi,j denote the transition probability from i to j, where i, j ∈ I;
• Q: transition probability matrix for treatment. In particular, Qi,j denotes the
transition probability from i to j, where i, j ∈ I;
• S0k,i: real data, the initial number of patients of illness degree i in school k.
5.3.2 Dynamic programming (DP) formulation
State Space: The state of the system at time t is a vector of schools with sub-vectors:
[[st,k,i]i∈I ]k=1,...,K , where the inner vector is a list of numbers of patients in different
states, and the outer vector combines all K schools.





xt,k = C ∀t = 1, . . . , T − 1;
xt,k ∈ {0, 1, 2, . . . , C} ∀t = 1, . . . , T − 1, k = 1, . . . , K;∑
i∈I
yt,k,i = Bxt,k, ∀t = 1, . . . , T − 1, k = 1, . . . , K;
yt,k,i ∈ [0, st,k,i], ∀i ∈ I, t = 1, . . . , T − 1, k = 1, . . . , K.
Transition: If treatment is not in place for school k, the states evolve from t to
t+ 1 based on the natural disease progression. On the other hand, if treatment is in
place, the allocation of capacity within school k needs to be considered:
1. For those who have treatment (i.e., yt,k,j), the transition has two parts: the
treatment effect (Q) and the natural disease progression (P ). Same as in [32],
we also assume treatment takes effect immediately;
2. For those who have no treatment (i.e., st,k,j − yt,k,j), the transition is solely
based on the natural disease progression (P ).
The relations between t and t+ 1 (t = 1, . . . , T − 1): ∀k,
st+1,k,i([st,k,j]j∈I , [xt,k, [yt,k,j]j∈I ]) =

∑






j∈I(st,k,j − yt,k,j)Pj,i, xt,k ≥ 1.
Rewards: As mentioned above, the sequence of events is defined as: state at the








Optimality equations with value function ut(St): The objective is to maxi-
mize the total QoLs from period 1 to T . The optimality equations are:
ut([[st,k,i]i∈I ]k=1,...,K) = Rt([[st,k,i]i∈I ]k=1,...,K) + max
a∈At
ut+1(St+1([st,k,i]i∈I , a)),
t = 1, . . . , T − 1;
uT ([[sT,k,i]i∈I ]k=1,...,K) = RT ([[sT,k,i]i∈I ]k=1,...,K).
5.3.3 Mixed-integer programming (MIP) formulation
The typical method to solve a dynamic problem with a finite horizon is backward
induction. However, for our problem, as shown in the computational study, the state
space and action space are too large to enumerate. A more efficient way is to formulate
it as a MIP and solve the MIP using solvers like Gurobi (Gurobi Optimization Inc.,
2016).










s.t. s1,k,i = S
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∀t = 1, . . . , T − 1, k = 1, . . . , K, i ∈ I; (18)
K∑
k=1
xt,k ≤ C, ∀t = 1, . . . , T − 1; (19)
∑
i∈I
yt,k,i ≤ Bxt,k, ∀t = 1, . . . , T − 1, k = 1, . . . , K; (20)
yt,k,i ≤ st,k,i, ∀t = 1, . . . , T − 1, k = 1, . . . , K, i ∈ I; (21)
xt,k ∈ Z+, ∀t = 1, . . . , T − 1, k = 1, . . . , K; (22)
yt,k,i ∈ Z+, ∀t = 1, . . . , T − 1, k = 1, . . . , K, i ∈ I. (23)
The objective function (16) maximizes the aggregate QoL months. (17) defines
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the initial states and (18) captures the state transition from period t to period t +
1. The capacity constraints among and within schools are presented in (19) and
(20) respectively. (21)–(23) define the range of the decision variables, where Z+ =
{0, 1, 2, . . .} denotes non-negative integers.
5.4 Heuristics
As the number of schools and patients increase, the size of the MIP gets very large,
which requires intensive computational resources, and thus poses a challenge to solve
the problem to optimality. In particular, the memory size becomes an issue. Even
for the 89 schools example in our computational study, it requires 150G memory
(exhausted the memory limit of the servers we can have) to load the entire problem
and solve it to optimality. It will become intractable if we extend the school list within
Atlanta Public School district to all the eligible public schools of the existing asthma
patients in Children’s Healthcare of Atlanta – Hughes Spalding campus (roughly 142
schools based on the visit data in year 2014). Therefore, it is critical to seek for
viable solutions. For that purpose, we develop two heuristics: one is an index-based
heuristic algorithm and the other one is a relaxing version of the base MIP model.
5.4.1 Heuristic 1 – index-based greedy algorithm
The idea of the heuristic comes from the optimization problem below to maximize
the QoLs one-step forward given the current state [st,k,i]k=1,...,K,i∈I in period t ∈
{1, 2, . . . , T − 1}:
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∀k = 1, . . . , K, i ∈ I; (25)
K∑
k=1
xt,k ≤ C; (26)
∑
i∈I
yt,k,i ≤ Bxt,k, ∀k = 1, . . . , K; (27)
yt,k,i ≤ st,k,i, ∀k = 1, . . . , K, i ∈ I; (28)
xt,k, yt,k,i are non-negative integers. (29)



















With (30), we can construct an index system for each illness degree.
Index for illness degrees: we rank the illness degree in a descending order of











Reorder set I to define IΦ = {I(1), I(2), . . .} given Φ(I(1)) ≥ Φ(I(2)) ≥ . . ..
Index for schools and capacity allocation policy: for a given period t ∈
{1, . . . , T −1}, we determine the capacity allocation variables of xt,k and yt,k,i by iter-
atively calculate the marginal improvement for each school k (denoted as Ψm(k), k ∈
{1, . . . , K}) assuming we will allocate a capacity B of one more day (indexed by
m ∈ {1, . . . , C}) to that school. The (̃·) denotes intermediate variables, where B̃ dy-
namically captures the remaining daily capacity when we allocate one-day capacity
to a given school, s̃k,m,i presents the number of patients of illness degree i in school
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k without appointment yet when we allocate capacity day by day in a given month,
and integer ỹk,m,i shows the allocation of one-day capacity to a given illness degree i
in school k. The heuristic for scheduling school and patients in period t is presented
as Algorithm 1.
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Algorithm 1: Greedy heuristic for scheduling school and patients in period
t = 1, 2, . . . , T − 1
1 Set s̃k,m=1,i = st,k,i∀k = 1, . . . , K, i ∈ I, xt,k = 0,∀k = 1, . . . , K and
yt,k,i = 0, ∀k = 1, . . . , K, i ∈ I;
2 for m = 1, . . . , C do
3 for k = 1, . . . , K do
4 Set B̃ = B,Ψm(k) = 0, ỹk,m,i = 0,∀i ∈ I ;
5 for i = I(1), I(2), . . . do
6 Define ỹk,m,i = bmin{s̃k,m,i, B̃}c and save it for later use;
7 Update Ψm(k) = Ψm(k) + Φ(i)ỹk,m,i ;
8 Update B̃ = B̃ − ỹk,m,i ;
9 if B̃ < 1 then
10 Break: jump out of the for-loop of i
11 Let k̃m = arg maxk Ψm(k). If there are ties, randomly pick a school k
among the ties;
12 Update decision variables for school k̃m: xt,k̃m = xt,k̃m + 1 and
yt,k̃m,i = yt,k̃m,i + ỹk̃m,m,i,∀i ∈ I ;
13 Update number of patients without appointment for schools k = 1, . . . , K
do
14 if k = k̃m then
15 s̃k,m+1,i = s̃k,m,i − ỹk,m,i,∀i ∈ I
16 else
17 s̃k,m+1,i = s̃k,m,i,∀i ∈ I








l∈I Qj,lPl,i, ∀k = 1, . . . , K, i ∈ I.
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5.4.2 Heuristic 2 – MIP relaxation algorithm
We propose a second heuristic by iteratively solving a series of MIPs relaxations. In
particular, we relax the integer constraints for future periods. We define parameter D
as the number of periods in which we impose integer constraints. In other words, the
time window for integer variables is specified as the current period to the succeeding
(D − 1) periods, in total D periods. As we move along decision periods, we fix the
decisions in the past periods, only re-solve the problem for the future periods.
MIP III (for tc and D): Heuristic at the current period tc, tc = 1, . . . , T−1









t,k , ∀t = 1, . . . , t
c − 1, k = 1, . . . , K, i ∈ I; (32)
yt,k,i = y
∗,tc−1
t,k,i , ∀t = 1, . . . , t
c − 1, k = 1, . . . , K, i ∈ I; (33)
xt,k ∈ {0, 1, . . .}, ∀t = tc, . . . , tc +D − 1, k = 1, . . . , K; (34)
yt,k,i ∈ {0, 1, . . .}, ∀t = tc, . . . , tc +D − 1, k = 1, . . . , K, i ∈ I; (35)
xt,k ≥ 0, ∀t = tc +D, . . . , T − 1, k = 1, . . . , K; (36)
yt,k,i ≥ 0, ∀t = tc +D, . . . , T − 1, k = 1, . . . , K, i ∈ I. (37)
(32)–(33) are integer constraints for the previous periods. Note that for the initial
case, i.e., tc = 1, the two sets of constraints are ignored from the formulation, and
there is no need to define x∗,0t,k and y
∗,0
t,k,i. Integer constraints apply for the current
period, tc, with a time window D, i.e. (34)–(35). In addition, we relax the integer
constraints for following periods after tc +D, i.e., (36)–(37).
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Algorithm 2: Relaxing period by period algorithm for scheduling school and
patients given a predefined time window D
1 Set tc = 1;
2 Solve MIP III for optimal solution x∗,1t,k (∀t = 1, . . . , T − 1, k = 1, . . . , K) and
y∗,1t,k,i(∀t = 1, . . . , T − 1, k = 1, . . . , K, i ∈ I);
3 for tc = 2, . . . , T −D do
4 Solve MIP III for optimal solution x∗,t
c
t,k (∀t = 1, . . . , T − 1, k = 1, . . . , K)
and y∗,t
c
t,k,i(∀t = 1, . . . , T − 1, k = 1, . . . , K, i ∈ I);
5 Report the optimal solution for MIP III for (T − 1).
5.5 Computational Study
In this section, we present both long-term and short-term decisions. We consider At-
lanta Public Schools (APS) district located in metro Atlanta. The APS school district
consists of 89 public elementary, middle, and high schools covering kindergarten (KK)
and 1st to 12th grades. In the first subsection, we report the input parameters to esti-
mate the size of asthma patients and define the scenarios and metrics. Because of the
curse of dimensionality, the model becomes intractable either when decision horizon
T becomes too long or the number of schools K increases. Therefore, we present a
long-term setting (i.e., T = 120 months) of one school, which is an aggregated version
of the 89 schools, and separately we consider the capacity allocations for the 89-school
system with a shorter decision horizon (i.e., T = 6, 12, 18, 24 months). We vary the
decision horizons, capacity levels, as well as initial distributions to understand their
impacts on the optimal solution. In addition, we report the optimality gap of our
models as well as the performance of our heuristics.
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5.5.1 Input parameters and metrics
There were in total 50669 students enrolled in KK to 12th grade in Fall 2016 [41].
Number of patients in each school is estimated and rounded to the nearest integer
by combining the enrollment data [41] and the prevalences of asthma by age (14.1%,
9.7%, 10% for ages 5–9, 10–14, 15–17 years respectively [45]) in Georgia. Combining
above inputs, the total number of patients in the 89 schools is estimated as 5975. The
daily capacity of one unit of asthma care mobile is set to be B = 16 (half an hour
per patient and eight hours per day) based on the estimation from Children’s.
We utilize the definitions in [32] for illness degrees of I = {1, 2, . . . , 16}, tran-
sition probability matrices (P and Q, see §5.7), and corresponding quality of life
(QoL) scores. In particular, [32] defines illness degrees jointly by control level (con-
trolled, improved, unchanged, and worsened) and severity level (mild intermittent,
mild persistent, moderate persistent, and severe persistent). The detailed definitions
are presented in Table 8.
Table 8: Definitions of illness degree level i and quality of life score (per month) from
Deo et al. [32].
Definition of illness degrees
Control level
Controlled Improved Unchanged Worsened
Severity level
Mild intermittent i = 1 i = 2 i = 3 i = 4
Mild persistent i = 5 i = 6 i = 7 i = 8
Moderate persistent i = 9 i = 10 i = 11 i = 12
Severe persistent i = 13 i = 14 i = 15 i = 16
Quality of life score 0.95 0.87 0.80 0.73
The initial number of patients in each illness degree of each school is governed by
an initial distribution. We define three initial distributions since we do not have such
data from Children’s and use them to generate instances in our computational study.
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In §5.8, we generate one instance as an example using each initial distribution and
report the size of patient by illness degree after aggregating schools.
• Initial distribution 1 - optimistic version: 80%, 10%, 5%, 5% of the pa-
tients start in control level of controlled, improved, unchanged, and worsened,
respectively, and they are uniformly distributed among severity levels;
• Initial distribution 2 - neutral version: 10%, 40%, 40%, 10% of the pa-
tients start in control level of controlled, improved, unchanged, and worsened,
respectively, and they are uniformly distributed among severity levels;
• Initial distribution 3 - pessimistic version: 5%, 5%, 10%, 80% of the
patients start in control level of controlled, improved, unchanged, and worsened,
respectively, and they are uniformly distributed among severity levels.
For the simplicity of presentation, we aggregate 16 illness degrees to three illness
groups. The definition is as follows.
• Illness group I (Best illness states) including i = 1, 5, 9, 13;
• Illness group II (Moderate illness states) including i = 2, 3, 6, 7, 10, 11, 14, 15;
• Illness group III (Worst illness states) including i = 4, 8, 12, 16.
Our code base is in MATLAB (MATLAB R2016a, The MathWorks Inc.) with the
optimization solver of Gurobi 6.5 [48]. The models run on servers with 8-core CPU
of Intel Xeon and memory of 56–150G. For each instance of optimization problem,
the solver runs up to two hours (controlled over all instance for a fair comparison) for
optimal solutions with a warm start of the better solution of heuristic algorithms 1
and 2 (with D = 1). We choose D = 1 because we found diminishing improvements
in objective values but large increases in computational time by setting D ≥ 2. For
technical details of the solutions, we define and compare the following metrics:
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• δ: Optimality gap (defined as the relative difference between upper bound and
optimal objective value, or equivalently,
zUB−zOpt
zOpt
, where zUB is the best upper
bound and zOpt is the objective value of the optimal solution at the time the
solver stops);
• τH: Heuristic gap, (defined as the relative difference between objective value of




where zH is the objective value of the heuristic), i.e., improvement of optimal
solution from that heuristic);
• Run time in seconds of the heuristic.
5.5.2 Capacity allocation of one school over a decision horizon of T = 120
months
Figures 14–15 compare the optimal solution and the Heuristic 1 solution side by side
for each of the three initial distributions. While the Heuristic 1 allocates almost
all capacity to the patients in the worst illness states, the optimal solution allocate
substantial capacity to both patients in the worst illness states (defined as treatment)
and patients in the moderate illness states (defined as prevention). As the system
evolves with time, we observe that number of patients in each illness group has a
huge difference between the two solutions: optimal solution ends up having a lot
more patients in the best states as well as the worst states, and Heuristic 1 solution
results in a majority of patients in the moderate states. The gap between Heuristic
1 and the optimal solution is quite small (0.40–1.45%, Table 9). Given the strong
performance and the huge advantage of Heuristic 1 in the run time (less than 1
second, Table 9), it is promising to reply on Heuristic 1 solution to schedule patients
in practice.
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Table 10 quantifies the improvement in the patients’ illness states with more ca-
pacity (C = 16, 32, 48, i.e., 1,2,3 units of vehicles respectively): more patients (74.62–
84.33% for C = 48 versus 30.17–38.42% for C = 16) are in the best illness states and
much fewer patients (2.83–7.07% for C = 48 versus 23.29–38.31% for C = 16) are in
the worst illness states. Combining with a fixed cost of $500,000 [76] to launch one
unit of vehicle on the road, as well as an estimation of incremental quality-adjusted life
years (QALYs), we can conduct cost-effectiveness analysis of the capacity size (Table
11). The cost-effectiveness analysis can inform Children’s decision of expanding the
current program.
In the domain of medical decision making, the QoL evaluation commonly intro-
duces a discounting factor (an annual discount rate of 3% or equivalently a monthly
rate of 0.25%) to consider time effect. In §5.9, we define a model formulation with a
discounting factor and present the corresponding solutions.
Figure 14: Capacity allocation to illness groups of one school over T = 120 months.
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Figure 15: Number of patients in illness groups of one school over T = 120 months.
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Table 9: Optimality gap and heuristic gaps of capacity allocation for one school with
T = 120 months.
Metric Initial distribution 1 (optimistic)
C = 16 C = 32 C = 48
δ 0.0022% 0.0050% 0.0072%
τH1 1.0598% 1.1508% 0.1250%
τH2 0.0000% 0.0000% 0.0000%
Run time (seconds) of heuristic 1 0.44 0.50 0.20
Run time (seconds) of heuristic 2 138.93 178.63 89.87
Metric Initial distribution 2 (neutral)
C = 16 C = 32 C = 48
δ 0.0020% 0.0046% 0.0066%
τH1 1.4526% 1.1555% 0.4307%
τH2 0.0000% 0.0000% 0.0000%
Run time (seconds) of heuristic 1 0.44 0.53 0.19
Run time (seconds) of heuristic 2 132.77 181.94 86.69
Metric Initial distribution 3 (pessimistic)
C = 16 C = 32 C = 48
δ 0.0019% 0.0042% 0.0064%
τH1 1.3238% 1.1007% 0.4022%
τH2 0.0000% 0.0000% 0.0000%
Run time (seconds) of heuristic 1 0.44 0.50 0.19
Run time (seconds) of heuristic 2 134.94 184.22 87.92
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Table 10: Optimal capacity allocation and percentage of patients in the illness groups
of one school over T = 120 months.
Initial distribution 1 (optimistic)
C = 16 C = 32 C = 48
Capacity in illness group I (redundant) 0 0 0
Capacity in illness group II and III 30464 60928 91392
% capacity in illness group III out of
those in illness groups II and III
80.48% 43.48% 21.75%
% patients in illness group I (best) 38.42% 63.51% 84.33%
% patients in illness group III (worst) 23.29% 3.78% 2.83%
Initial distribution 2 (neutral)
C = 16 C = 32 C = 48
Capacity in illness group I (redundant) 0 0 0
Capacity in illness group II and III 30464 60928 91392
% capacity in illness group III out of
those in illness groups II and III
76.49% 48.38% 25.04%
% patients in illness group I (best) 31.30% 54.69% 76.50%
% patients in illness group III (worst) 30.07% 5.20% 3.55%
Initial distribution 3 (pessimistic)
C = 16 C = 32 C = 48
Capacity in illness group I (redundant) 0 0 0
Capacity in illness group II and III 30464 60928 91392
% capacity in illness group III out of
those in illness groups II and III
78.39% 52.58% 28.84%
% patients in illness group I (best) 30.17% 52.73% 74.62%
% patients in illness group III (worst) 38.31% 10.63% 7.07%
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Table 11: Incremental quality-adjusted life years (QALYs) over T = 120 months by
increasing capacity.
QALYC=32−QALYC=16 QALYC=48−QALYC=32
Initial distribution 1 (optimistic) 3057.95 1841.50
Initial distribution 2 (neutral) 3220.11 1974.87
Initial distribution 3 (pessimistic) 3299.59 2064.06
5.5.3 Capacity allocation of 89 schools over a decision horizon of up to
T = 24 months
Figures 16–17 show the capacity allocation of optimal solution and Heuristic 1 solution
over T = 24 months, and number of patients in illness groups as a result of the two
solutions. Similar to the capacity allocation of one school over a long decision horizon,
for the pessimistic initial distribution with C = 16 (one vehicle), Heuristic 1 allocates
all capacity to treatment and results in a large portion of patients in the moderate
illness states over time. The heuristic gap of Heuristic 1 is 0.10%, 0.22%, and 0.08%
for initial distribution 1, 2, and 3 respectively (Table 12), which further suggests that
Heuristic 1 has a strong performance. This is in line with the literature that such
type of index-based myopic policy can perform very well [32, 79, 80, 81]. In addition,
we find that the strong performance of Heuristic 1 persists in the sensitivity analyses
of transition probability matrices P and Q, and QoL scores (§5.10). In addition, a
setting with more schools (for example, in the school districts not limited to APS) or
a decision horizon longer than T = 24 months will explode the memory size and easily
make the MIP intractable. In that case, heuristics become the only option to solve
for capacity allocation in those settings since they are showing a comparable solution
quality to the MIP solutions (Table 12) when the MIP solutions are available.
Tables 13–14 quantify the portion of patients in the best and worst illness states
as a result of the optimal solution of the scenarios with various capacity (C =
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16, 32, 48, i.e., 1,2,3 vehicles respectively) and/or various decision horizons (T =
6, 12, 18 months). Not surprisingly, as capacity and/or decision horizon increase,
more patients end up in the best illness states.
Figure 16: Capacity allocation to illness groups of 89 schools over T = 24 months.
Figure 17: Number of patients in illness groups of 89 schools over T = 24 months.
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Table 12: Optimality gap and heuristic gaps of capacity allocation for 89 schools
with T = 24 months.
Metric Initial distribution 1 (optimistic)
C = 16 C = 32 C = 48
δ 0.2612% 0.6076% 1.2508%
τH1 0.1024% 0.0440% 0.0074%
τH2 0.0000% 0.0005% 0.0003%
Run time (seconds) of heuristic 1 0.38 0.42 0.44
Run time (seconds) of heuristic 2 1858.16 1859.81 2464.06
Metric Initial distribution 2 (neutral)
C = 16 C = 32 C = 48
δ 0.1007% 0.3853% 0.5074%
τH1 0.2177% 0.3192% 0.3535%
τH2 0.0000% 0.0000% 0.0003%
Run time (seconds) of heuristic 1 0.39 0.40 0.43
Run time (seconds) of heuristic 2 1604.68 2015.57 2251.34
Metric Initial distribution 3 (pessimistic)
C = 16 C = 32 C = 48
δ 0.0978% 0.2066% 0.3633%
τH1 0.0840% 0.1804% 0.1946%
τH2 0.0001% 0.0000% 0.0000%
Run time (seconds) of heuristic 1 0.42 0.39 0.46
Run time (seconds) of heuristic 2 1722.79 1405.68 2363.21
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Table 13: Optimal capacity allocation and percentage of patients in the illness groups
of 89 schools over T = 24 months.
Initial distribution 1 (optimistic)
C = 16 C = 32 C = 48
Capacity in illness group I (redundant) 7 256 2803
Capacity in illness group II and III 5881 11520 14861
% capacity in illness group III out of
those in illness groups II and III
71.26% 38.22% 26.86%
% patients in illness group I (best) 54.06% 66.19% 74.23%
% patients in illness group III (worst) 13.42% 9.16% 7.05%
Initial distribution 2 (neutral)
C = 16 C = 32 C = 48
Capacity in illness group I (redundant) 0 3 85
Capacity in illness group II and III 5888 11773 17579
% capacity in illness group III out of
those in illness groups II and III
73.74% 54.85% 35.33%
% patients in illness group I (best) 21.06% 33.63% 47.26%
% patients in illness group III (worst) 28.31% 13.10% 9.90%
Initial distribution 3 (pessimistic)
C = 16 C = 32 C = 48
Capacity in illness group I (redundant) 0 1 34
Capacity in illness group II and III 5888 11775 17630
% capacity in illness group III out of
those in illness groups II and III
86.16% 76.43% 54.71%
% patients in illness group I (best) 16.15% 27.62% 40.24%
% patients in illness group III (worst) 59.70% 36.17% 25.51%
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Table 14: Optimal capacity allocation and percentage of patients in the illness groups
of 89 schools for pessimistic initial distribution 3.
Metric T = 6 T = 12 T = 18
C = 16
Capacity in illness group I (redundant) 0 0 0
Capacity in illness group II and III 1280 2816 4352
% capacity in illness group III out of
those in illness groups II and III
100.00% 100.00% 94.30%
% patients in illness group I (best) 7.48% 9.86% 12.65%
% patients in illness group III (worst) 72.95% 65.65% 61.62%
C = 32
Capacity in illness group I (redundant) 0 0 0
Capacity in illness group II and III 2560 5632 8704
% capacity in illness group III out of
those in illness groups II and III
100.00% 99.11% 88.38%
% patients in illness group I (best) 10.52% 15.13% 21.04%
% patients in illness group III (worst) 63.87% 48.48% 40.76%
C = 48
Capacity in illness group I (redundant) 0 0 13
Capacity in illness group II and III 3840 8448 13043
% capacity in illness group III out of
those in illness groups II and III
100.00% 81.75% 65.91%
% patients in illness group I (best) 13.19% 22.43% 30.89%
% patients in illness group III (worst) 54.92% 37.35% 28.68%
§5.11 presents how the capacity allocation to schools with various initial distribu-
tions and school sizes. In addition, §5.12 compares a variety of heuristic and policies.
The optimal solution of 89 schools can still be very useful even we find that the Heuris-
tic 1 solution has a very small gap (0.08% for the pessimistic initial distribution). By
implementing the optimal solution instead of Heuristic 1, the absolute improvement
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of objective value is about 96 QoL months for 5975 patients (on average of 0.8 week
improvement per patient over 24 months), which is substantial in practice. We be-
lieve the improvement results from a better school selection and a better balance of
treatment and prevention.
5.6 Conclusions
We develop a dynamic programming model to solve the capacity allocation problem
for school-aged asthma patients within metro Atlanta. We formulate it as a MIP and
propose two heuristics to solve it. We are the first to propose a model framework to
consider school selection along with resources allocation within each selected school
by taking disease progression into consideration. The numerical results show that the
heuristics perform sufficiently well within a reasonable computational time, and can
be useful especially when a larger number of schools or a longer decision horizon is
considered and MIP is intractable due to the memory size. In addition to the policy of
curing the sickest patients, controlling the disease progression among moderately sick
patients is also important. The framework that we propose can be implemented in
practice to determine the optimal schedule of the asthma program, and our findings
are very useful for decision makers to plan for the school-based asthma program.
5.7 Appendix A: transition probability matrices
The transition probabilities matrices P and Q are based on Deo et al. [32] and we
adjust some digits to make sure the summation of each row equals one (see Tables
15–16).
80
Table 15: The transition probability matrix P for natural disease progression based
on Deo et al. [32].
Illness degree
i 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1 0.97 0.01 0.01 0.01 0 0 0 0 0 0 0 0 0 0 0 0
2 0 0.85 0.08 0.07 0 0 0 0 0 0 0 0 0 0 0 0
3 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
4 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0
5 0 0 0 0 0.93 0.04 0.01 0.02 0 0 0 0 0 0 0 0
6 0 0 0 0 0 0.8 0.12 0.08 0 0 0 0 0 0 0 0
7 0 0 0 0 0 0 0.93 0.07 0 0 0 0 0 0 0 0
8 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0
9 0 0 0 0 0 0 0 0 0.93 0.03 0.02 0.02 0 0 0 0
10 0 0 0 0 0 0 0 0 0 0.79 0.11 0.1 0 0 0 0
11 0 0 0 0 0 0 0 0 0 0 0.94 0.06 0 0 0 0
12 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0
13 0 0 0 0 0 0 0 0 0 0 0 0 0.9 0.04 0.03 0.03
14 0 0 0 0 0 0 0 0 0 0 0 0 0 0.81 0.08 0.11
15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.94 0.06
16 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
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Table 16: The transition probability matrix Q for treatment based on Deo et al.
[32].
Illness degree
i 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2 0.72 0.28 0 0 0 0 0 0 0 0 0 0 0 0 0 0
3 0.7 0.21 0.09 0 0 0 0 0 0 0 0 0 0 0 0 0
4 0.31 0.58 0.07 0.04 0 0 0 0 0 0 0 0 0 0 0 0
5 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
6 0 0 0 0 0.59 0.41 0 0 0 0 0 0 0 0 0 0
7 0 0 0 0 0.37 0.46 0.17 0 0 0 0 0 0 0 0 0
8 0 0 0 0 0.24 0.67 0.06 0.03 0 0 0 0 0 0 0 0
9 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
10 0 0 0 0 0 0 0 0 0.47 0.53 0 0 0 0 0 0
11 0 0 0 0 0 0 0 0 0.35 0.45 0.2 0 0 0 0 0
12 0 0 0 0 0 0 0 0 0.25 0.63 0.09 0.03 0 0 0 0
13 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0
14 0 0 0 0 0 0 0 0 0 0 0 0 0.57 0.43 0 0
15 0 0 0 0 0 0 0 0 0 0 0 0 0.42 0.42 0.16 0
16 0 0 0 0 0 0 0 0 0 0 0 0 0.35 0.53 0.09 0.03
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5.8 Appendix B: one instance of initial number of patients
corresponding to initial distributions 1–3
Table 17: One instance of initial patient size of each illness degree generated from
initial distributions 1 (optimistic), 2 (neutral), 3 (pessimistic) respectively.
Illness degree i Initial distribution 1 Initial distribution 2 Initial distribution 3
1 1184 128 70
2 129 606 58
3 80 579 139
4 75 155 1201
5 1195 148 90
6 143 567 58
7 64 623 161
8 85 149 1178
9 1227 153 77
10 146 620 76
11 72 600 176
12 84 156 1200
13 1199 145 72
14 161 600 73
15 63 615 150
16 68 131 1196
5.9 Appendix C: capacity allocation of one school over a
decision period of T = 120 months with a discounting
factor
We introduce a discounting factor and aggregate the QoLs-to-go after 120 months.
In particular, we substitute the objective function of MIP I by adding a discount-
ing factor for the quality of life scores over time, i.e., a discounting factor as λ =
1
1+γ
with a monthly discount rate of γ = 0.25%. In addition, we adjust the re-
wards in the ending period to combine all the values as if the illness state remains











i∈I bisT,k,i. The constraints and decision
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variables are the same as those in MIP I, i.e., constraints of (17)–(23) with decision
variables of xt,k, yt,k,i,∀t = 1, . . . , T − 1, k = 1, . . . , K, i ∈ I. Table 18 shows a gap of
1.7–2.1% between Heuristic 1 and the optimal solution.
Table 18: Optimality gap and heuristic gaps of capacity allocation for one school
with T = 120 months and a discount rate of γ = 0.25%.
Metric Initial distribution 1 (optimistic)
C = 16 C = 32 C = 48
δ 0.0025% 0.0047% 0.0083%
τH1 1.8991% 1.8328% 0.1695%
τH2 0.0000% 0.0002% 0.0000%
Run time (seconds) of heuristic 1 0.16 0.19 0.25
Run time (seconds) of heuristic 2 74.63 99.44 75.14
Metric Initial distribution 2 (neutral)
C = 16 C = 32 C = 48
δ 0.0022% 0.0046% 0.0084%
τH1 2.0972% 1.8377% 0.2781%
τH2 0.0000% 0.0000% 0.0011%
Run time (seconds) of heuristic 1 0.32 0.25 0.26
Run time (seconds) of heuristic 2 106.68 102.99 71.52
Metric Initial distribution 3 (pessimistic)
C = 16 C = 32 C = 48
δ 0.0023% 0.0045% 0.0098%
τH1 2.0383% 1.8216% 0.2711%
τH2 0.0000% 0.0001% 0.0000%
Run time (seconds) of heuristic 1 0.32 0.41 0.25
Run time (seconds) of heuristic 2 105.60 150.99 70.70
5.10 Appendix D: sensitivity analysis of transition proba-
bility matrices P and Q, and QoL scores for capac-
ity allocation of 89 schools over a decision period of
T = 24 months with one vehicle C = 16
We conduct probabilistic sensitivity analysis for transition probability matrices P
and Q independently (Algorithm 2 in [95]). Table 19 shows that the gap between
Heuristic 1 and the optimal solution is consistently small even with different P and
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Q. It suggests that Heuristic 1 is able to capture the dynamics of the system very
well and it is a strong candidate to be used in the capacity allocation problem when
the MIP solution is not available.
Table 19: Range of Heuristic 1 gap in probabilistic sensitivity analysis of P and Q
(10 instances along with the baseline).
Heuristic 1 gap (τH1)
mean min max
Initial distribution 1 (optimistic) 0.09% 0.05% 0.17%
Initial distribution 2 (neutral) 0.20% 0.09% 0.34%
Initial distribution 3 (pessimistic) 0.10% 0.01% 0.24%
The same as in [32], we also consider the concave and convex version of QoL
scores:
• Concave QoL scores: 0.95, 0.90, 0.84, 0.73 for controlled, improved, unchanged,
worsened illness degrees respectively;
• Linear QoL scores (used as the baseline scenarios in the main text): 0.95, 0.87,
0.80, 0.73 for controlled, improved, unchanged, worsened illness degrees respec-
tively;
• Convex QoL scores: 0.95, 0.82, 0.76, 0.73 for controlled, improved, unchanged,
worsened illness degrees respectively.
Table 20: Heuristic 1 gap for concave and convex QoL scores.
Concave QoL scores Convex QoL scores
Initial distribution 1 (optimistic) 0.06% 0.11%
Initial distribution 2 (neutral) 0.04% 0.36%
Initial distribution 3 (pessimistic) 0.04% 0.37%
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It is true that under the current settings (linear QoL scores) the Heuristic 1
prioritizes treatment over prevention. However, in a more general setting, this might
not be the case. In fact, in the convex QoL scores cases, Heuristic 1 is no longer
a treatment-prioritized solution. In addition, Heuristic 1 considers the number of
patients by illness degrees for each school and compare the total improvement among
schools. Therefore, Heuristic 1 is not equivalent to a treatment-prioritized policy and
the strong performance of Heuristic 1 does not imply that treatment-prioritized policy
has a good performance as well. We believe that the small gap between Heuristic 1
and optimal solution is not because Heuristic 1 is a treatment-prioritized policy but
because Heuristic 1 can well capture the main dynamics of the illness progression and
respond to the current system states in each decision period.
5.11 Appendix E: capacity allocation by patient size and
initial distribution for 89 schools over a decision pe-
riod of T = 24 months with one vehicle C = 16
We group schools by their patient sizes (each group has a similar number of schools):
number of patients between 7 and 52 (small size schools), 53 and 72 (medium size
schools), 73 and 182 (large size schools), and uniformly assign initial distributions
1,2,3 to the 89 schools and test for 15 random instances. Figure 18 shows the av-
erage percentage of capacity (restricted to those for illness groups II and III, i.e.,
non-redundant capacity) by school size and initial distribution. We observe that
the capacity allocation is driven by schools with a large size of patients and initial
distribution 3.
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Figure 18: Average percentage of capacity allocation by patient size and initial
distribution.
5.12 Appendix F: comparison of various policies for capac-
ity allocation in 89 schools over a decision period of
T = 24 months with one vehicle C = 16
We compare the objective value of each of the following policies and the relative gaps
compared to the optimal capacity allocation for 89 schools (Table 21).
• Heuristic 1: index-based heuristic algorithm (Algorithm 1);
• Do nothing : the policy of not scheduling any patients (the baseline in [32]);
• Treatment maximization: a policy of maximizing the total number of patients
in the worst illness states being scheduled (the optimal solution of a MIP with
an objective function of maximizing treatment);
• Treatment-prioritized heuristic: a myopic policy of prioritizing schools based on
the number of patients in the worst illness states and scheduling only patients
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in the worst illness states of the prioritized schools (school and patient selection
can change over time);
• Prevention maximization: a policy of maximizing the total number of patients
in the moderate illness states being scheduled (the optimal solution of a MIP
with an objective function of maximizing prevention);
• Prevention-prioritized heuristic: a myopic policy of prioritizing schools based
on the number of patients in the moderate illness states and scheduling only
patients in the moderate illness states of the prioritized schools (school and
patient selection can change over time);
• Fixed schedule policy : a myopic policy of prioritizing schools based on the initial
number of patients in the worst illness states and randomly scheduling patients
in each period (the list of schools and days per month of visiting each school are
fixed at the beginning of the entire decision horizon, and the schedule repeats
every month);
• One aggregating school policy : optimal solution of an one school setting (relax-
ation of base MIP by removing school boundaries).
The policy of doing nothing provides a lower bound of the objective value (zNull) of
any policy. Compared to that, the fixed schedule policy can only close about 20–50%
( zFixed−zNull
zOpt−zNull
) of the gap to optimal solution in terms of the objective value, although it is
the easiest policy to implement. The Heuristic 1 consistently outperforms treatment-
/prevention-prioritized heuristics. Compared to the policy of doing nothing, our
Heuristic 1 can close about 95–99% ( zH1−zNull
zOpt−zNull
) of the policy gap.
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Table 21: Objective value and policy gap of various policy with C = 16 (1 vehicle)
and T = 24 months.
Policies Metric Initial distribution 1 Initial distribution 2 Initial distribution 3
Optimal capacity allocation of
89 schools
Objective value 126334.32 118009.87 113187.56
Heuristic 1
Objective value 126205.00 117752.91 113092.43
Policy gap 0.10% 0.22% 0.08%
Do nothing
Objective value 121074.22 111990.39 106645.19
Policy gap 4.16% 5.10% 5.78%
Treatment maximization
Objective value 124889.98 117279.94 112492.13
Policy gap 1.14% 0.62% 0.61%
Treatment-prioritized heuristic
Objective value 124722.43 116409.81 112074.62
Policy gap 1.28% 1.36% 0.98%
Prevention maximization
Objective value 122856.85 115078.84 108752.92
Policy gap 2.75% 2.48% 3.92%
Prevention-prioritized heuristic
Objective value 123522.65 115160.75 107489.19
Policy gap 2.23% 2.41% 5.03%
Fixed schedule policy
Objective value 122642.05 114875.76 108044.24
Policy gap 2.92% 2.66% 4.54%
One aggregating school policy
Objective value 126930.26 118162.00 113331.62




This thesis has applied Operations Research techniques in two healthcare applications,
i.e., DS screening and asthma care for school-aged patients. We have shown the great
potential to improve patients outcomes by using our optimization frameworks. Our
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[83] Schmidt, P., Hörmansdörfer, C., Golatta, M., and Scharf, A., “Anal-
ysis of the distribution shift of detected aneuploidies by age independent first
trimester screening,” Archives of Gynecology and Bbstetrics, vol. 281, no. 3,
pp. 393–399, 2010.
[84] Song, K., Musci, T. J., and Caughey, A. B., “Clinical utility and cost of
non-invasive prenatal testing with cfdna analysis in high-risk women based on
a us population,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 26,
no. 12, pp. 1180–1185, 2013.
[85] Spencer, K., “Age related detection and false positive rates when screening
for Down’s Syndrome in the first trimester using fetal nuchal translucency and
maternal serum free βhCG and PAPP-A,” BJOG: An International Journal of
Obstetrics & Gynaecology, vol. 108, no. 10, pp. 1043–1046, 2001.
[86] St. Louis Children’s Hospital, “Healthy kids express - asthma program.”
http://www.rmhc.org/ronald-mcdonald-care-mobile, 2016. Accessed: May
28, 2016.
[87] United States Department of Health and Human Services (US
DHHS), Centers for Disease Control and Prevention (CDC),
National Center for Health Statistics (NCHS), Division of Vi-
tal Statistics, “Natality public-use data 2014, on CDC WONDER Online
Database.” http://wonder.cdc.gov/natality-current.html. Accessed: July
4, 2017.
[88] Wald, N. and Hackshaw, A., “Tests using multiple markers,” in Antenatal
and Neonatal Screening (Wald, N. J. and Leck, I., eds.), pp. 23–57, Oxford:
Oxford University Press, 2000.
98
[89] Wald, N. J., Rudnicka, A. R., and Bestwick, J. P., “Sequential and
contingent prenatal screening for down syndrome,” Prenatal Diagnosis, vol. 26,
no. 9, pp. 769–777, 2006.
[90] Wald, N., Rodeck, C., Hackshaw, A., Walters, J., Chitty, L., and
Mackinson, A., “First and second trimester antenatal screening for down’s
syndrome: the results of the serum, urine and ultrasound screening study (su-
russ),” Journal of Medical Screening, vol. 10, no. 2, pp. 55–104, 2003.
[91] Wald, N., Rodeck, C., Hackshaw, A., Walters, J., Chitty, L., and
Mackinson, A., “First and second trimester antenatal screening for down’s
syndrome: the results of the serum, urine and ultrasound screening study (su-
russ),” Health Technology Assessment, vol. 7, no. 11, pp. 1–88, 2003.
[92] Walker, B., Ashwood, E. R., Jackson, B. R., and Lagrave, D., “A
tradeoff analysis of risk cutoffs for the quadruple serum screen for down syn-
drome,” Prenatal Diagnosis, vol. 33, no. 12, pp. 1201–1206, 2013.
[93] Yan, J., Ayer, T., Keskinocak, P., and Caughey, A. B., “Preference-
sensitive risk-cutoff values for prenatal-integrated screening test for Down syn-
drome,” Prenatal Diagnosis, vol. 35, no. 7, pp. 645–651, 2015.
[94] Yan, J., Ayer, T., Keskinocak, P., and Caughey, A. B., “Age-based
differences in the predictive accuracy of a one-size-fits-all risk-cutoff value in
prenatal integrated screening for Down syndrome,” Prenatal Diagnosis, p. to
appear, 2017.
[95] Zhang, Y., Wu, H., Denton, B. T., Wilson, J. R., and Lobo, J. M.,




Jia Yan was born and grew up in China. She received her Bachelor and Master de-
grees in Industrial Engineering from Tsinghua University (Beijing, China) in 2009
and 2011, respectively. After that she came to the United States and began to pur-
sue her Ph.D. in Operations Research in the H. Milton Stewart School of Industrial
and Systems Engineering at Georgia Institute of Technology. In 2014, she received a
Master degree in Operations Research from Georgia Institute of Technology. She won
2017 Graduate Student Paper Competition of Society for Health Systems with the
paper “Age-Specific Risk-Cutoff Values in Prenatal-Integrated Screening for Down
Syndrome Considering Fairness”. She is interested in learning and applying opera-
tions research and statistical methodologies to various areas and making impacts.
100
